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 I 
ABSTRACT 
In physiological conditions glia in the central nervous system (CNS) can 
produce and release protective factors such as anti-oxidant molecules and 
neurotrophic factors (Sofroniew et al., 2010). Events that impinge on CNS 
homeostatic balance can induce local inflammatory responses (Carson et al., 
2006). Reactive glia can participate producing pro-inflammatory mediators 
such as chemokines, cytokines, purines and free radicals.  
Toll-like receptors (TLRs) are involved in injury responses of nervous 
system tissue and in neuropathic pain. Here we have investigated the cross-
talk mechanisms between glial cells in the CNS making use of an in vitro 
cellular model, evaluating how glia respond to TLR agonists based on 
cytokine synthesis and release as well as TLR mRNA/protein expression as 
readouts. 
In order to analyze specific molecular parameters involved in the genesis 
and maintenance of inflammation, purified microglia and astrocyte-enriched 
cultures were generated from cerebral cortex of 1-2 day-old rat pups. For 
some experiments the enriched astrocyte cultures were purified by 
treatment with L-leucyl-L- leucine methyl ester (L-LME), which selectively 
depletes cultures of microglia. Activation of microglia and astrocytes (± L-
LME) was achieved by treatment with lipopolysaccharide (LPS, TLR4 
agonist); zymosan (TLR2 agonist) and poly(I:C) (TLR3 agonist) for 6 and 24 
hours.  
Gene expression analysis (Real Time-polymerase chain reaction) revealed 
the ability of microglia to induce mRNA coding for interleukin-1β (IL-1β), 
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). In contrast, 
purified (nominally microglia-free) astrocyte cultures were not responsive 
to TLR agonists – unlike their astrocyte-enriched counterpart. Mediator 
production and release into the culture medium (analysed by ELISA) 
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confirmed that microglia themselves respond to pathogenic stimuli. 
Utilizing flow-cytometric analysis we evaluated the expression of TLR 
receptors on the cell surface (TLR2/4) or in endosomal membranes (TLR3) 
after 1, 6 or 24 hours of stimulation with TLR agonists.  
Non-neuronal cell responsiveness to pathogenic stimuli is almost always 
linked to the production of inflammatory mediators. In this context we 
asked if the apparent inability of purified astrocytes to express a pro-
inflammatory phenotype was dependent on the absence of the relevant 
TLR. Using confocal microscopy, stimulation with LPS conjugated with a 
fluorochrome showed the presence of TLR4 on the astrocyte cell surface. 
and Western blot analysis revealed the presence of the co-receptors MD2 
and CD14. As consequence, purified astrocytes have been studied in flow 
cytometry to evaluate alteration in TLR protein expression. 
Moreover, we reconstituted the inflammatory profile in astrocyte cell 
cultures by adding fixed numbers of purified microglia (10% of 
contaminating cells final). Although the latter 'co-cultures' express pro-
inflammatory cytokines after TLR agonist stimulation the absolute levels 
are inferior to those measured in enriched astrocytes (<5% of 
contaminating microglia. 
To further address the issue of whether microglial cell activation in the 
presence of astrocytes results from either physical interaction between 
cell membranes or chemical induction mediated by the release of 
mediator(s) into the culture medium, a “Transwell insert” system was used. 
The astrocyte/microglia co-culture paradigm described here may provide a 
useful starting point to elucidate the molecular mechanisms underlying 
astrocyte- and microglia-specific responses pertaining to, although not 
limited to, CNS inflammation, especially where TLR activation plays a role. 
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RIASSUNTO 
Nel sistema nervoso centrale (SNC), le cellule gliali in condizioni fisiologiche 
producono e rilasciano sostanze protettive come molecole anti-ossidanti e 
fattori neurotrofici (Sofroniew et al., 2010). Tutti gli eventi che alterano 
l’equilibrio omeostatico inducono una risposta infiammatoria locale (Carson 
et al., 2006). La glia reattiva partecipa producendo mediatori 
dell’infiammazione come chemochine, citochine, purine e radicali liberi.  
I recettori Toll-like (TLRs) sono coinvolti nelle risposte da danno indotto a 
carico del tessuto nervoso e nel dolore neuropatico.  
Nel nostro studio abbiamo investigato i meccanismi di comunicazione tra le 
cellule della glia attraverso la realizzazione di un modello cellulare in vitro 
idoneo alla valutazione della risposta gliale al trattamento con agonisti dei 
TLRs, valutando sia l’espressione di molecole associate all’attivazione dei 
recettori sia la modulazione genica/proteica degli stessi TLRs.  
Per poter valutare meglio la genesi e la progressione dello stato 
infiammatorio, colture di microglia purificata e colture arricchite in 
astrociti (≥95%) sono state ottenute dal sacrificio di ratti neonati di 2 
giorni e dalla successiva dissezione corticale. Per i nostri esperimenti le 
colture arricchite di astrociti sono state trattate con L-leucil-L-Leucina 
estere metilico (L-LME) al fine di ottenere una coltura purificata di 
astrociti (≥99%). 
L’attivazione della microglia e degli astrociti (± L-LME) è stata indotta dal 
trattamento con lipopolisaccaride (LPS, agonista del TLR4), zymosan 
(agonista del TLR2) e poli(I:C) (agonista del TLR3) per 6 e 24 ore. 
L’analisi dell’espressione genica (in Real Time PCR) ha permesso di 
dimostrare la capacità delle cellule della glia di indurre la trascrizione di 
mRNA codificante per interleuchina-1β (IL-1β), interleuchina-6 (IL-6) e 
tumor necrosis factor-α (TNF-α). La coltura purificata di astrociti non 
 IV 
risponde al trattamento con agonisti TLRs, diversamente dalla coltura 
arricchita in astrociti in cui persiste una piccola percentuale di cellule della 
microglia.  
La produzione e il rilascio nel terreno di coltura di mediatori 
dell’infiammazione (dosaggio ELISA) confermano che la microglia risponde 
allo stimolo patogenico. Inoltre le analisi di citofluorimetria hanno permesso 
di valutare l’espressione dei TLRs sulla membrana cellulare (TLR2/4) e sulla 
membrana degli endosomi (TLR3) dopo 1 ora, 6 ore e 24 ore di trattamento.  
La responsività delle cellule non-neuronali ad uno stimolo lesivo viene 
solitamente valutata sulla base della capacità delle cellule di produrre 
mediatori pro-infiammatori. Alla luce di queste evidenze abbiamo voluto 
chiarire se l’apparente assenza di responsività della coltura purificata di 
astrociti, dipendesse da alterazioni a carico della struttura recettoriale. 
Utilizzando la microscopia confocale, abbiamo marcato le cellule con LPS 
coniugato con un fluorocromo dimostrando la presenza del TLR4 sulla 
superficie cellulare degli astrociti e le analisi di Western Blot hanno 
permesso di confermare anche la presenza dei co-recettori CD14 e MD2. 
In particolare, lo studio sugli astrociti purificati è stato approfondito 
mediante citofluorimetria per valutare le alterazioni a carico 
dell’espressione proteica dei TLRs.  
Un’ulteriore batteria di esperimenti è stata condotta ripristinando il profilo 
infiammatorio aggiungendo un numero fisso di cellule di microglia (per un 
totale del 10% di cellule contaminanti) ad una coltura purificata di astrociti. 
Sebbene la ri-aggiunta di microglia su un monostrato di astrociti purificati 
(≥99%) ripristini il profilo infiammatorio della coltura, in termini di valore 
assoluto la quantità di citochine prodotte e rilasciate è comunque inferiore 
ai valori misurati nella coltura arricchita in astrociti (in cui la contaminante 
microgliale è ≤5%). Per meglio chiarire se l’attivazione microgliale in 
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presenza di astrociti dipendesse da il contatto fisico tra le membrane 
cellulari oppure da fattori chimici abbiamo allestito un sistema “Transwell”. 
Il paradigma descritto della co-coltura astrociti/microglia protrebbe 
rappresentare un utile punto di partenza per chiarire i meccanismi 
molecolari che sottendono le specifiche risposte delle singole popolazioni 
cellulari all’infiammazione, non solo del SNC, specialmente in tutti quei 
meccanismi che prevedono il coinvolgimento dei recettori TLRs.  
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1. INTRODUCTION 
 
1.1. The central nervous system 
The central nervous system (CNS) integrates information it receives from, 
and coordinates and influences the activity of all parts of the body.  This 
phenomenon, named homeostasis, is fundamental for the organism’s survival. 
The CNS in its most fundamental state is composed of neurons and glia. 
Neurons use their electrical properties to transmit information by means 
of electrical and chemical signals. They are organized in circuits and are 
usually considered the most important cellular component of the brain.  
Glia lack electrical properties and have always been considered as 
supporting cells for neurons. We now know that glial cells are not only 
heterogeneous, but also play critical roles in supporting the health of 
neurons as well as possessing signaling properties in their own right. CNS 
and peripheral nervous system glia can be distinguished on the basis of 
morphology, function and location. For example in mammals, glia are 
classified as astrocytes, oligodendrocytes (and the related Schwann cells) 
and microglia. 
The presence of glial cells is conserved across the animal kingdom, from 
man to also the simplest invertebrate, no doubt a reflection of their 
fundamental importance to the organism. There is a correlation between 
animal size and the percentage of glial cells in brain. For example, in 
Drosophila 25% of the brain is made up of glia; this proportion rises to 65% 
in mouse and about 90% in man (Allen and Barres, 2009). 
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1.1.1. The role of microglia in the CNS 
The CNS has been considered as immune-privileged because of the 
presence of resident macrophagic cells, the microglia. The latter can be 
easily distinguished from other glial cells by origin, morphology, gene 
expression pattern and function (Sajo and Glas, 2011). Microglia are 
considered to derive from cells of monocytic lineage and invade the brain 
early in development (Farber and Kettenmann, 2005). Of the total CNS glial 
cell content, some 5-20% comprises microglia, depending on the specific 
brain region (Sajo and Glas, 2011; Lawson et al., 1990). 
In the healthy brain, microglia are characterized by ramified branches 
that emerge from the cell body and communicate with surrounding neurons 
and other glial cells. This morphology represents the “resting” state. Upon a 
change in the brain environment, microglia quickly adopt an “ameboid” 
activated phenotype and migrate to the site of injury, proliferate and 
release pro-inflammatory mediators including cytokines, chemokines, 
reactive oxygen species (ROS) and nitric oxide (NO). When prolonged, such 
cellular activation may contribute to neurodegeneration and neoplastic 
disease progression (Fig. 1.1). Microglia are considered also as central 
players of CNS immune responses (Sajo and Glas, 2011; Farber and 
Kettenmann, 2005). 
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Figure 1.1 Microglial activity states throughout the activation process. Microglia in the 
surveillance state (traditionally termed ‘resting’ state)—constantly survey their 
environment for signals that would indicate a potential threat to CNS homeostasis. The 
appearance of such ‘activating’ signals (infection, trauma or cell impairment) or loss of 
constitutive ‘calming’ signals triggers a transition to an alerted state. Cells hence further 
commit to distinct reactive phenotypes, constituted by transcriptional profiles and non-
transcriptional changes, and enter their executive phase (for example, release of cytokines 
and chemokines, phagocytotic activity).  
Some microglia may not retransform to a completely naive status but remain in a ‘post-
activated’ state. These cells could retain subtle changes, for example, in transcriptional 
activity that affect their sensitivity to constitutive (calming) signals or alter responses to 
subsequent stimulation. Post-activated microglia could thus have acquired some experience 
(indicated as memory in the figure by a floppy disk icon) (Hanosh et al., 2007). 
 
 
1.1.1.1. Identification of microglia populations   
Since microglia and macrophages exhibit the same lineage origin, they 
share many antigenic markers. For this reason the lack of unique microglial 
antigens has hindered until now their identification. Immunohistochemistry 
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or immunofluorescence techniques can be applied to brain slices to detect 
in vitro microglial cells. The downside of these procedures, however, is that 
they fail to distinguish microglia from macrophages. Antibodies raised 
against complement receptor type 3, CR3 (Graeber et al., 1989; Kingham et 
al., 1999) recognize the complex CD11b/CD18 (also named OX42), 
expressed by rat and mouse microglia and usually used as a classical marker 
of microglia (Robinson et al., 1986). Alternatively, the cluster of 
differentiation type 68 (CD68) (also named ED-1), a lysosomal protein, can 
be used to identify microglia (Graeber et al., 1990; Slepko & Levi 1996; 
Kingham et al., 1999; Hooper et al., 2005). High levels of CD68 expression 
are associated with macrophages and activated microglia, while low levels of 
expression are associated with quiescent ramified microglia (Graeber et al., 
1990; Slepko & Levi 1996; Kingham et al., 1999). 
Microglial identification is often performed using flow cytometry, which 
enables one to determine differences as well as quantify antigen expression 
levels. Ramified parenchymal microglia possess the phenotype 
CD11b+, CD45low (Ford et al., 1995; Becher & Antel 1996; Kingham et al., 
1999; Hooper et al., 2005) while other CNS and peripheral macrophages 
exhibit the phenotype CD11b+, CD45high . Moreover, ionized calcium binding 
adaptor molecule 1 (Iba1), a protein that mediates Ca2+ signals, can be used 
to selectively detect microglia.  
Brain microglia reportedly exhibit antigen heterogeneity (Ito et al., 1998; 
Perry et al., 1985). For example, an antibody raised against OX-42 was 
described to react with ramified but not perivascular microglia (Graeber et 
al., 1988). By contrast, an anti-ED2 antibody reacted with perivascular but 
not ramified microglia (Raeber et al., 1989). This heterogeneity can be a 
reflection of different subpopulations of microglia. Ito and colleagues 
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(1998) demonstrated that Iba1 recognizes ramified microglia throughout 
the white and grey matter and perivascular microglia in the brain, 
suggesting that different subpopulations of microglia share a common 
pattern of Iba1 expression (Ito et al., 1998). 
 
1.1.1.2. Physiological properties of microglia 
Microglia cell cultures have been used to identify surface membrane 
receptors and channels. Classical neurotransmitters engage microglial 
receptors in physiologic conditions and trigger increases in Ca2+ 
concentration, a transient increase in K+ conductance or open an intrinsic 
ionic pore. 
Different subtypes of glutamate receptors are expressed by microglia: 
these include α-amino-3-hydroxy-5-methyl-4-isoxazole propionate and 
kainate. Their activation induces the release of tumor necrosis factor-α 
(TNF-α) (Noda et al., 2000) but can also reduce microglia activation by 
lipopolysaccharide (LPS) (Taylor et al., 2002), a component of the outer 
membrane of Gram-negative bacteria. Further, microglial cell γ-
aminobutyric acid (GABA)B receptors can control K
+ conductance and 
modulate the immune response reducing the release of interleukin-6 (IL-6) 
in cells stimulated with LPS (Farber and Kettenmann, 2005, Kuhn et al., 
2004). 
Adenosine triphosphate (ATP) is a nucleoside important not only as a key 
energy substrate of cells but also as a cell signaling molecule. Purinergic 
P2Y and P2X receptors are expressed on the cell surface (Farber and 
Kettenmann, 2005). In microglia ATP can trigger complex responses upon 
binding its target receptors. In particular, activation of P2X receptor 
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subtype 7 in LPS-‘primed’ microglia can induce the release of interleukin-1β 
(IL-1β (Facci et al., 2014; Ferrari et al., 1997; Honda et al., 2001). 
Microglia, moreover express β1- and β2- adrenergic receptors. Stimulation 
with norepinephrine increases intracellular cyclic adenosine monophosphate 
concentration and subsequent mRNA level of IL-1β (Tanaka et al., 2002). 
Several different in vitro models have been used to characterize microglia 
in pathologic conditions. The most common of these involves exposing cells 
to LPS, which can trigger the release of numerous neurotransmitters and 
molecules associated with inflammation such as chemokines, cytokines and 
ROS (Table 1.1) (Farber and Kettenmann, 2005). 
 
 
 
Table 1.1. The effect of neurotransmitter receptor stimulation on LPS-induced release 
of mediators (Farber and Kettenmann, 2005) 
 
The same pro-inflammatory mediators released by activated microglia can 
recognize specific receptors expressed on their own plasma membrane and 
thus act in an autocrine fashion (Farber and Kettenmann, 2005). 
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1.1.2. The role of astrocytes in the CNS 
Rudolf Virchow was the first to introduce the term “neuroglia”. He defined 
these cells as small and round-shaped, which filled-up the extracellular 
space and were part of the connective tissue. While the term neuroglia is 
still used our knowledge of these cells has dramatically changed (Wang and 
Bordey, 2008). In mammals, astrocytes are generated during gliogenesis 
that begins late in embryonic development and continues during the 
neonatal and postnatal period. Since different astrocyte lineages can be 
distinguished, it is possible to postulate that not all originate in the same 
manner (Wang and Bordey, 2008). 
Astrocytes are found throughout the entire CNS in a contiguous and non-
overlapping manner. There are no CNS regions devoid of astrocytes or 
closely related cells (Sofroniew and Vinters, 2009). Because of their 
morphology and anatomical location, astrocytes can be divided into two main 
subtypes, called protoplasmic and fibrous. The former are located in grey 
matter, while the latter are found throughout the white matter (Sofroniew 
and Vinters, 2009). 
Both cell subtypes make contacts with blood vessels. In particular, 
synapses are usually enveloped by the processes of protoplasmic 
astrocytes, while nodes of Ranvier are tightly wrapped by the processes of 
fibrous astrocytes (Sofroniew and Vinters, 2009). It has been estimated 
that in hippocampus and cerebral cortex several hundred dendrites from 
multiple neurons are contacted by branching processes of a single 
astrocyte (Sofroniew and Vinters, 2009; Bushong et al., 2002; Halassa et 
al., 2007; Ogata et al., 2002). 
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1.1.2.1. Identification of astrocytic populations   
Glial cells can be characterized using specific molecular markers. 
Astrocytes are commonly identified by the presence of intermediate 
filaments (glial fibrils). The major component of glial fibrils, glial fibrillary 
acid protein (GFAP) has become a typical marker in immunohistochemical 
techniques. However this astrocytic marker has limitations. GFAP can be 
clearly detected only in reactive astrocytes during pathological events. It 
cannot be considered as a absolute marker because of its low detection 
level in all non-reactive astrocytes in healthy brain. To overcome this 
impasse double-staining with multiple markers is possible (Sofroniew and 
Vinters, 2009). Large-scale genetic analysis of the astrocyte trascriptome 
allowed one to identify a large number of molecules typical of these cells 
compared to neurons and oligodendrocytes (Sofroniew and Vinters, 2009; 
Chahoy et al., 2008). 
An alternative way to characterize astrocytes is by the use of flow 
cytometry, whose high sensitivity permits the detection of low protein 
expression. The immunophenotype of astrocytic cells can be well-
characterized based on different expression levels in GFAP-positive cells 
related to specific parameters of dimension and cell surface complexity 
(forward and side scatter, FCS and SSC). 
 
1.1.2.2. Physiological properties of astrocytes 
Astroglia were at one time considered to be in a certain sense the brain’s 
‘glue’, providing structural support for neurons. We now know that the story 
is far more complex, whereby glial cells are active players in CNS well-
being. Astrocytes outnumber other cells in CNS. 
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The different subtypes of astrocytes share a common set of biophysical 
characteristics. These macroglia all express potassium (K+) and sodium 
(Na2+) channels, and are able to evoke inward currents without generating 
action potentials - unlike neurons. For this reason astrocytes are referred 
to as “passive” cells, but not necessarily “silent” or unresponsive (Sofroniew 
and Vinters, 2009; Wang et al., 2008). An intriguing property of astrocytes 
is their ability to generate intracellular calcium (Ca2+) waves that can be 
considered as a form of astrocyte excitability. Cell behaviors will be 
determined necessarily by intracellular ion species and concentration.  Ionic 
movements can be triggered by activity-dependent transmitter release 
from neurons. Likewise, it can elicit the release of gliotransmitters from 
astrocytes, thereby altering neuronal excitability (Sofroniew and Vinters, 
2009; Halassa et al., 2007; Perea et al., 2009; Shigetomi et al., 2008).  
Neighboring astrocytes can communicate with each other by means of ion 
waves traversing gap junctions. Gap junction coupling of astrocytes into 
multicellular networks participates both in normal function and CNS 
disorders (Sofroniew and Vinters, 2009; Nedergaard et al., 2003; 
Shigetomi et al., 2008; Volterra et al., 2005). The above phenomenon is now 
believed to allow astrocytes to play a direct role in synaptic transmission. 
Astrocytes express also a repertoire of cell surface metabotropic and 
ionotropic receptors. Furthermore, they express receptors for growth 
factors, chemokines, steroids and receptors involved in innate immunity 
(Wang et al., 2008). It is important to keep in mind that astrocytes are also 
a critical component of the blood-brain barrier, which can become 
compromised in various neuropathologies – especially when inflammation is 
involved (Fig. 1.2). 
 
 10 
 
1.1.3. Microglia and astrocyte interplay 
Microglia are the principal resident immune cell type in the CNS (‘brain 
macrophages’) and as such represent the first line of defense, constantly 
surveilling their environment to detect pathogens and injury. Activation 
takes place immediately after the detection of exogenous substances, such 
as LPS, or pro-inflammatory mediators, such as IL-1β (Davalos et al., 2005). 
Microglia undergo rapid proliferation in order to increase their number for 
the upcoming “battle”. Indeed immunostaining at this stage shows an 
upregulation of OX42 (Kim and de Vellis, 2005). Their migration to the 
injured area is accompanied by promotion of cell proliferation through the 
secretion of pro-inflammatory factors. All these events allow microglia to 
destroy the invading exogenous agent, remove potential harmful debris, and 
secrete growth factors promoting tissue repair to return to homeostasis 
(Fig. 1.2) (Kreutzberg, 1996). 
 
 
Figure 1.2. Activity states of microglia. L e f t  p a n e l : Microglia in normal tissue 
constantly screen their environment (1). Equipped with receptors for a plethora of 
molecules, they can immediately sense signs of disturbed structural and functional 
integrity. Neurons may also deliver signals which keep microglia in this surveillance mode, 
indicating normal function (2). Besides parenchymal microglia, perivascular macrophages 
are in closer association with blood vessels (3). Subsets of circulating monocytes may 
replenish perivascular cells. C e n t e r  p a n e l :  (4). The response is probably supported 
by neighboring astrocytes releasing, for example, purinoreceptor ligands (5). Microglia 
can produce neurotrophic factors to support endangered neurons (6). Disruption of 
ongoing communication through calming signals would allow an endangered neuron to call 
for microglial assistance (7). Such neurons can also emit signals indicating disturbed 
functions using molecules that are not usually released (at all or at critical 
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concentrations; (8)). Microglial cells may be able to limit further damage and restore 
normal homeostasis. Right panel: stronger insults to the CNS (infectious challenge or 
significant tissue injury) may trigger more drastic changes in the functional phenotype 
of microglia. Excessive acute, sustained (chronic) or maladaptive responses of microglia 
may lead to substantial impairment of neurons and glia (9). Failure of protection and an 
active contribution to damaging cascades have been attributed to activated glial cells in 
many pathologic scenarios in the CNS (Hanish et al., 2007). 
 
Activation of microglia and astrocytes arises at different stages. For 
instance in neuropathic pain, microglia are activated earlier than are 
astrocytes. The latter respond more slowly to spinal nerve injury (Colburn 
et al., 1997). In particular, pro-inflammatory cytokines released by 
activated microglia can facilitate the activation of astrocytes. This process 
may rely mainly on IL-1β as mediator because of its fast release and ability 
to induce other inflammatory mediators (John et al., 2005). Once 
activated, the levels of intracellular Ca2+ in astrocytes would increase and 
spread to other, neighboring astrocytes (Fig. 1.3) (Liu et al., 2011). Further, 
Ca2+ waves generated in activated astrocytes can result in rapid motility 
and morphological changes (Scemes, 2000) which can propagate to 
neighboring microglia (Schipke et al., 2002). 
 
Figure 1.3. Schematic representation of Ca2+ waves. ATP mediates the propagation of 
elevated intracellular calcium. It can contribute to astrocyte-astrocyte communication and 
distant microglia activation (Liu et al., 2011) 
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Blocking purinergic receptors with antagonists, such as suramin, can fully 
prevent this propagation (Guan et al., 1997) – pointing to ATP as the 
principal mediator (Cotrina et al., 1998). Purinergic receptors are highly 
expressed on microglia, thus placing ATP in a position to mediate astrocyte-
to-microglia communication (Honda et al., 2001; Noremberg et al., 1997; 
Shigemoto-Mogami et al., 2001; Suzuki et al., 2004). In addition, microglia 
respond to cytokines released from ATP-stimulated cells (Bianco et al., 
2005; Hide et al., 2000). Astrocytes propagating long-distance Ca2+ waves 
can contribute to microglia activation at a distance (Nedergaard and 
Dirnagl, 2005, Liu et al., 2011). 
 
1.1.4. Inflammation 
Inflammation and neurological diseases are intimately connected. Although 
fundamentally a protective cellular response aimed at removing injurious 
stimuli and initiating the healing process, when prolonged, inflammation 
overrides the bounds of physiological control and eventually becomes 
destructive. The degree and extend of inflammation is a function of the 
interplay between the initiating insult (pathogen and/or tissue trauma) and 
the immune system (Carson et al., 2006; Lo et al., 1999; Medzhitov et al., 
1998). Inflammation increasingly surfaces as a key element in the 
pathobiology of chronic pain and neuropathic pain, neurodegenerative 
diseases, stroke, spinal cord injury, and perhaps even neuropsychiatric 
disorders (Carson et al., 2006; Melchior et al., 2006; Herbert et al., 2005; 
others). A plethora of pro-inflammatory cytokines, eicosanoids, and other 
immune neurotoxins, have been found in cerebrospinal fluid and/or 
affected brain regions of patients with neurodegenerative disorders 
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(Nagatsu et al., 2000). Glia provide a link also between neuroinflammation 
and neuropathic pain (Thacker et al., 2007); microglia, in particular, show 
increased activity in multiple pain processing pathways in response to 
peripheral injury (Gao and Ji, 2010).  
 
A key advance in the field of pain research has been the insight that not 
only neurons, but also immune-derived non-neuronal cells, such as microglia, 
as well as other non-neuronal cells (astrocytes, mast cells), are involved in 
pain signaling. The participation of these non-neuronal cells allows for the 
transmission of pain messages from peripheral nociceptors to the spinal and 
supraspinal levels. Further, these cell types are able to communicate with 
each other – as noted above. This has important implications for pain 
treatment, as pain pharmacology has traditionally targeted neurons while 
ignoring these non-neuronal elements and their interactions. This, no doubt, 
accounts for the fact that current analgesics predominately modulate pain 
transduction and transmission in neurons and have limited success in 
controlling disease progression. Understanding how glia respond to 
pathogens will be important in the design of more efficacious anti-
inflammatory therapeutics. 
 
1.2. Toll-like receptors 
The immune system preserves homeostasis and protects the organism 
against disease. To function properly, an immune system must detect a wide 
variety of external agents, known as pathogens, and distinguish between 
self and non-self. In many species, the immune system can be subdivided in 
two branches: the innate and the adaptive immune systems. The former is 
cell-mediated and represents the first line of defense, while the latter is 
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defined as humoral and is responsible for the production of antibodies and 
formation of long-lived memory cells (Kelian, 2005). 
Microglia, together with macrophages, dendritic cells, natural killer cells 
and neutrophils are components of the innate immune system and express a 
predetermined subset of germline-encoded receptors, called pattern 
recognition receptors (PRRs). PRRs are a large family of receptors 
classified as membrane-bound, cytoplasmic or secreted. Toll-like receptors 
(TLRs) are cell surface PRRs and are considered crucial environmental-
sensing molecular motifs termed pathogen-associated molecular patterns 
(PAMPs) and endogenous molecules termed damage-associated molecular 
patterns (DAMPs) (Hanke and Kelian, 2011). 
PAMPS are a heterogeneous group of molecules originating from pathogens 
that range from lipids to lipopeptides, proteins, and nucleic acids (Table 
1.2) (Kawai and Akira, 2006). 
 
Table 1.2. Pathogen-associated molecular patterns and TLRs. PAMPs originate from 
bacteria, fungi, parasites and viruses (Akira et al., 2006). 
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DAMPs activate the innate immune system through TLRs (Table 1.3) (Karico 
et al., 2004; Tsan and Gao, 2004), and can initiate and perpetuate immune 
response in the non-infectious inflammatory response, in contrast to 
PAMPs. The former can simultaneously control homeostasis and/or disease 
progression. Until now their regulatory mechanism has remained unclear 
(Kelian, 2008). 
 
 
Table 1.3. Damage-associated molecular patterns. Endogenous TLR ligands originate 
after cell disruption (Lee et al., 2013) 
 
After ligand engagement TLRs undergo conformational changes that allow 
them to interact with five different adaptor molecules: MyD88, Mal, TRIF, 
TRAM and SARM. In turn, this leads to activation of a phosphorylation 
cascade and signal transduction, culminating in induction of the nuclear 
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factor kB (NF-KB), mitogen-activated protein kinase (MAPKs) and/or 
interferon (IFN)-regulatory factor (IRF) signalling pathways. The end 
result is the modulation of expression levels of immune response genes 
(Hanke and Kelian, 2011). 
These cells participate in both innate and adaptive immune response. 
Indeed they allow the neuroinflammation induction secreting pro-
inflammatory mediators and regulating T-cell responses (Aloisi et al., 2001; 
Hanish et al., 2002). 
The TLR family includes 13 receptors in rodent and 11 in human (Hanke and 
Kelian, 2011). All CNS cell types express these receptors but at different 
levels. Indeed microglia, as immune-competent cells, express all currently 
known TLRs, whereas other neural cells (e.g. astrocytes) express a more 
limited TLR repertoire (Fig. 1.4) (Hanke and Kelian, 2011). The presence of 
TLRs in both microglia and astrocytes is necessary for the amplification of 
pro-inflammatory responses. Table 1.4 provides a summary of what is 
currently known about TLR expression/function in neurons and glia (Kelian, 
2005). 
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Figure 1.4 Expression of TLR family members in CNS cells 
 
Table 1.4. TLR expression in CNS cell types. Consequences of TLR stimulation might 
relate to those already known from immune cell populations. However, differences 
regarding receptor complex organization, signaling and associated downstream effects 
might reveal yet unknown effects (Hanke and Kelian, 2011). 
 
1.2.1. TLR function, localization and signaling 
TLRs are transmembrane receptors composed of an extracellular domain 
with a ligand-binding site and an intracellular domain with a signaling Toll-
IL-1 receptor (TIR) site. The TLR family members show considerable 
sequence divergence which allows them to recognize a wide range of 
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chemical structures. The TIR domain, in contrast, is highly conserved 
between family members and recognizes the TIR domain containing adaptor 
molecules. 
The localization and trafficking of TLRs within the cell is an important 
mechanism to sense signals from the external environment. At the same 
time, ligand binding represents a negative feedback to avoid excessive 
activation of TLR signaling (Fig. 1.5). Trafficking of extracellular TLR2/4 
and intracellular TLR3/7/9 have been extensively investigated (McGettrick 
and O’Neill, 2010). 
 
 
 
Figure 1.5. TLR Trafficking and signaling  
PAMP engagement induces conformational changes of TLRs that allow homo- or 
heterophilic interactions of TLRs and recruitment of adaptor. TLR5 uses MyD88 and 
activates NF-kB resulting in induction of inflammatory cytokines. TLR2 is a l so  
expressed within the endosome and can induce type I IFN via IRF3 and IRF7 in 
response to viruses. TLR4, which is expressed on the cell surface, initially 
transmits signals through NF-kB and then is transported into phagosomes, where 
i t  activates IRF3 signaling to induce type I IFN.  
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TLR3, TLR7, and TLR9 are localized mainly to the endoplasmic reticulum in the steady-
state and traffic to the endosomal compartment, where they engage their ligands. 
TLR3 activates the TRIF-dependent pathway to induce type I IFN and inflammatory 
cytokines. TLR7 and TLR9 activate NF-kB and IRF7, respectively (Kawai and Akira, 
2011). 
 
Initial studies using cell lines transfected with TLR4 showed no 
responsiveness to LPS. It was later determined that an additional molecule, 
named MD2, was needed for LPS signaling. MD2 is physically bound to TLR4 
forming a complex, and recognizes the lipid A portion of LPS, the 
biologically active component (Shimazu et al., 1999; Viriyakosol et al., 
2000). TLR4 is currently the best-characterized TLR. Together with MD2 
and CD14, a glycosylphosphatidyl inositol (GPI)-anchored receptor belonging 
to PRRs, these form a complex that binds LPS.  
A single LPS molecule can regulate TLR4 cell surface expression at two 
levels: the amount of TLR4 moving from Golgi to plasma membrane; the 
amount of TLR4 moving from plasma membrane to endosomes. In resting 
human monocytes TLR4 protein can be detected both in Golgi and on the 
cell surface (Husebye et al., 2006; Latz et al., 2002). MD2 has an essential 
role in regulating TLR4 distribution and, as a consequence, in LPS 
responsiveness (Nagai et al., 2002; Shimazu et al., 1999). There is good 
evidence to confirm that a continuous cycling of TLR4 between Golgi and 
plasma membrane occurs after LPS engagement. This cycle leads to 
interaction with molecular transducers and finally cytosolic NF-kB 
activation (Verstrepen et al., 2008; Windheim et al., 2008). Within 15 
minutes after LPS binding, TLR4 translocates from cell surface to 
endosome via a clathrin-dependent dynamic process (Husebye et al., 2006; 
Palsson-McDermott et al., 2009). It was initially thought that this receptor 
movement served to allow its degradation (Husebye et al., 2006), although 
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this does not now appear to be the case. Indeed, TLR4 internalization is 
essential for a functional signaling pathway. While blocking TLR4 
trafficking had no effect on NF-kB signaling, phosphorylation of IRF3 was 
completely abolished. Upon LPS stimulation, MyD88 translocates rapidly to 
the plasma membrane where it co-localizes with Mal and TLR4 in lipid rafts. 
This interaction leads to activation of the MyD88-dependent NF-kB 
pathway (Botelho et al., 2000). During endocytosis Mal dissociates from 
TLR4, which allows the receptor to remain in contact with TRAM and 
activate the IRF3 pathway. 
TRIF is expressed in the cytosol of resting cells. Upon LPS stimulation, it 
relocates within 30 minutes to plasma membrane lipid rafts and early 
endosomes with TLR4. It subsequently co-localizes with TRAM and CD14 
forming a complex that leads to IRF3 activation (Tanimura et al.,2008; 
Palsson-McDermott et al., 2009; Honda et al.,2004; Wong et al., 2009). 
These results proved clearly that internalization of TLR4 serves not merely 
to down-regulate receptor signaling, but also to allow activation of the 
TRAM-TRIF pathway and IFN-γ synthesis (Kagen et al., 2008). 
 
Nilsen and colleagues (2008) used resting monocytes to demonstrate TLR2 
expression on the cell surface, in early endosomes, and late 
endosomes/lysosomes. Further studies using cell lines detected this 
receptor also in Golgi. The activity of TLR2 is strictly related to the co-
expression of CD14. Indeed, peptidoglycan (PGN) or lipotheicoic acid are 
first recognized by CD14; this complex then interacts with TLR2/TLR1 
and/or TLR2/TLR6 heterodimers. These data have been confirmed using 
TLR2 knock-out (KO) or CD14 KO mice, and suggest a common functional 
mechanism for these two receptors (Kelian et al., 2008). As with TLR4, 
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upon stimulation TLR2 accumulates in lipid rafts and in phagosomes 
(Triantafilou et al., 2002; Ozinsky et al., 2000; Takahashi et al., 2008; 
Underhill et al., 1999). Likewise, antigens bound to TLR2 are presented to 
the major histocompatibility complex (MHC) class II to induce proliferation 
of mouse C-specific human CD4+ T cell clones (Schjetne et al., 2003). TLR2 
internalization is required for the production of IFNγ but not TNFα. These 
data support the idea that TLR2 and TLR4 have distinct subcellular 
locations and mediate two signaling pathways (Barbalat et al., 2009). 
 
TLR3/7/8/9 are nucleic acid-sensing TLRs and are localized to the 
endoplasmic reticulum (ER), and possess retention signals located in 
different sites depending on the TLR (Leifer et al., 2006; Nishiya et al., 
2005). It remains unclear if other extracellular TLRs have an export signal 
or simply lack the retention signal (McGettrick and O’Neill, 2010). Upon 
stimulation TLR3/7/9 move from the ER to endosomes (Johnsen et al., 
2006; Latz et al., 2005). Delivery of internalized nucleic acid (DNA, single-
stranded RNA, double-stranded RNA) to the endosome is pivotal to 
interaction with these TLRs (Kawai and Akira, 2010). Further, also LPS 
treatment can trigger TLR7 and TLR9 movement from ER to endosomes, 
even though it is not a specific ligand for these two receptors (Johnsen et 
al., 2006; Yi et al., 1998).  
Self-derived nucleic acids do not activate innate immune responses under 
physiological conditions, as they are normally degraded by serum nucleases 
before being bound by TLRs in the endolysosomes. For this reason the 
intracellular localization of nucleic acid-sensing TLRs is fundamental for 
avoiding contact with self-nucleic acid (Barton et al., 2006). 
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1.2.2. TLRs expression in microglia and astrocytes 
1.2.2.1. TLR2 
TLR2 is constitutively expressed on microglia and its expression is up-
regulated by agents such as PGN and lipotheicoic acid (Kelian et al., 2008; 
Laflamme et al., 2001, 2003). Given microglia heterogeneity in the CNS and 
the fact that subpopulations of microglia can differ in their receptor 
pattern, there is much interest in elucidating TLR distribution. For 
example, in primary cultures of cortical mouse astrocytes, cells obtained 
from TLR2 KO animals were protected against PGN, demonstrating the 
pivotal role of TLR2 in recognizing S. aureus during infection (Kelian et al., 
2005).  
TLR2 expression in primary astrocytes from mice is rather consistent 
across studies, although some inconsistencies have been reported using 
cells from other sources, e.g. human. Some reports describe the presence 
of TLR2 mRNA (Bsibsi et al., 2002), but others failed to detect the 
receptor on the cell surface (Farina et al., 2005). Using In situ 
hybridization in mouse brain stimulated with LPS or cytokines, some 
reports show the presence of TLR2 mRNA in microglia but not astrocytes 
(Rivest, 2003; Owens, 2005). These conflicting data may be due to species 
differences, route of administration of PAMP in vivo, and the extent of 
astrocyte purity in in vitro studies. Another issue to consider is the length 
of time during which astrocytes are co-cultured with microglia before 
purification. Indeed, it is possible that astrocytes are more reminiscent of 
the in vivo interactions between these cells (Kelian, 2008). 
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1.2.2.2. TLR3 
Several studies have demonstrated the expression of TLR3 in microglia 
(Bsibsi et al., 2002; Olson and Miller, 2004). Treatment of these cells with 
a mimetic of the natural ligand, poly(I:C), induces the production of IL-1β, 
IFNγ and IL-6. In contrast with other TLRs, the synthetic agonist cannot 
induce up-regulation of the receptor (Olson and Miller, 2004). Using 
astrocytes purified from human white matter, Bsibsi and colleagues (2002) 
demonstrated receptor expression by measuring release of pro-
inflammatory mediators after treatment with poly(I:C). 
 
 
1.2.2.3. TLR4 
As mention before, TLR4 is crucial for the recognition of LPS, a Gram-
negative cell wall component. In early studies, stimulation with LPS 
activated both TLR4 and TLR2 (Yang et al., 1998; 1998). It was later 
discovered that lipoprotein impurities in the LPS preparation were 
responsible for TLR2 activation. Removal of these contaminants eliminated 
the stimulatory effect on TLR2, but not TLR4 (Hirshfeld et al., 2000; 
Tapping et al., 2000).  
Microglia express TLR4 on their cell surface (Kitamuraet al., 2001; Qin et 
al., 2005). Microglial cell activation can occur in a TLR4-independent 
manner with high doses of LPS, indicating the engagement of lower-affinity 
receptors (Kelian, 2008; Perera et al., 1997). CD14 interacts with TLR4 to 
maximize LPS responsiveness (in effect, a co-receptor). Primary microglia 
express CD14 as demonstrated using CD14 KO mice. This receptor is 
essential for low-dose LPS responseiveness (Esen and Kelian, 2005). 
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Protracted LPS stimulation (i.e. 72 hrs) is able to induce apoptosis in 
microglia via IFN-γ release. This autocrine stimulation is driven by TLR4 
activation (Jung et al., 2005). Under these conditions other factors are 
released, including NO, superoxide and other cytokines. Collectively these 
factors are capable of inducing cell death also in susceptible neurons and 
oligodendrocytes when co-cultured with microglia. These results were 
confirmed using primary cultures from TLR4-deficent mice (Lenhardt et al., 
2004). 
In contrast to microglia, TLR4 expression on astrocytes remains an open 
question. Several groups have demonstrated cell surface TLR4 in vitro 
(Farina et al., 2005) or in vivo (Laflamme and Rivest, 2001; Lehnardt et al., 
2002; 2003), while others detected low, constitutive expression of TLR4 in 
astrocytes that increased upon cell activation (Bsibsi et al., 2002; Bowman 
et al., 2003). The divergent results for TLR4 expression can probably be 
explained in the same way as for TLR2 discrepancies already discussed. In 
addition, the sensitivity of TLR detection methods applied may be a factor. 
 
1.2.2.4. Other TLRs 
Numerous studied have been conducted to detect the presence of other 
TLRs. The available data are equivocal, given the lack of functional studies, 
for example, using KO mice. 
TLR1 and TLR6 form a heterodimer with TLR2 and mediate Gram-positive 
recognition (Ozynsky et al., 2000; Takeuchi et al., 2002; 2003). They are 
both expressed on microglia (Bsibsi et al., 2002; Kelian et al., 2002; Olson 
and Miller, 2004) and astrocytes (Carpentier et al., 2005). 
TLR5 binds flagellin, a monomer of bacterial flagella. Astrocytes and 
microglia express this receptor on their surface (Bowman et al., 2003; 
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Carpentier et al., 2005; Bsibsi et al., 2002; Olson and Miller, 2004). In 
particular Bowman and colleagues (2003) demonstrated that astrocytes 
treated with flagellin release IL-6 and up-regulate expression of TLR5, its 
target, but also TLR2 and TLR4. 
TLR7 and TLR8 share a high degree of primary sequence homology; each 
binds GU-rich single stranded RNA (ssRNA). Since mammalian RNA 
contains GU-rich sequences, these TLRs can be involved as an autoimmune 
trigger in patients with systemic Lupus erythrematosus, who show high 
levels of auto-antibodies against RNA (Lau et al., 2005). While no studies 
have been conducted treating glia with TLR7/8 agonists, there is evidence 
supporting their expression in microglia and astrocytes (Bsibsi et al., 2002; 
Olson and Miller, 2004; Carpentier et al., 2005). 
TLR9 mediates its responses when binding to bacterial DNA, viral DNA and 
synthetic oligodeoxynucleotides containing unmethylated CpG motifs. 
Several studies have reported TLR9 expression on rodent primary microglia 
in culture. Astrocytes are also activated by TLR9 agonists. TLR9 activation 
in microglia results in the production of numerous pro-inflammatory 
mediators and activation of inducible NO synthase. These effects have not 
been verified in primary human astrocytes (Kelian, 2008). 
TLR10 is an orphan receptor, and is capable of forming heterodimers with 
TLR1 and TLR2 (Hasan et al., 2005). TLR11 is involved in uropathogenic 
bacterial identification, for example, E. coli (Zhang et al., 2004). 
Considering the limited pattern expression of TLR10 and TLR11, it seems 
unlikely - although this remains to be completely excluded - that either one 
is to be found in CNS glia (Kelian, 2008). 
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1.2.3. TLRs in CNS health and disease 
The discovery of TLRs in mammals has greatly improved our understanding 
of immune system reactions to diverse pathogens. Although the classical 
role of TLRs has been linked to the removal of microbial agents, these PRRs 
in reality impact several aspects of CNS homeostasis and non-infectious 
diseases/damage (Hanke and Kelian, 2011) (Table 1.5). 
 
 
Table 1.5. TLRs role in the healthy (a) and diseased (b) brain 
 
For instance, beyond pathogen recognition TLRs in the brain are activated 
in several pathogenic conditions such as following neuronal cell injury. 
TLR2- and TLR4-KO mice have been used to demonstrate a role for both 
PRRs in mediating neuronal cell death after stroke (Lenhardt et al., 2007; 
Ziegler et al., 2007; Hyakkoku et al., 2010). During experimental ischemia, 
microglia show increased TLR2 expression. The mechanism leading to 
neuronal cell death, however, remains unclear. It will be important to 
understand if TLR2 over-expression is a consequence of inflammation or 
 27 
 
has a functional impact on disease. TLR2- and TLR4-KO mice have been 
utilized to evaluate parameters such as infarct size, neurological deficits 
and neuronal cell damage (Tang et al., 2007). The endogenous ligand(s) that 
trigger TLR activation after stroke have yet to be identified. Considering 
the extensive inflammation and neuronal cell injury, it is not unreasonable 
to presume that a mixture of elements released after cell death are 
responsible (Hanke and Kelian, 2011). 
Another interesting aspect of the role of TLRs in neuropathology is that of 
painful neuropathy. TLR4 has a critical role in the induction phase of 
behavioral hypersensitivity. Using two different TLR4 mutant mouse 
strains, Tanga et al. (2004, 2005) showed these animals to have an 
attenuated mechanical allodynia and thermal hypersensitivity in comparison 
to wild-type mice. Moreover there was a decreased expression of activated 
microglial markers and a reduction in pro-inflammatory mediator release. 
Making use of MyD88- and TLR2-KO mice to dissect the TLR signaling 
pathway, Owens and colleagues (2005) investigated the connection between 
glial responses and axonal degeneration in the hippocampal dentate gyrus. 
In this model axonal terminals located in the entorhinal cortex are 
transected to reproduce the pathology (Jersen et al., 1997, 1999; Finsen et 
al., 1999). Axotomy in MyD88-KO mice led to a reduction in both 
macrophages and lymphocytes infiltrating the hippocampus. In addition, 
microglia that normally increase at specific times post-lesion, were reduced 
in hippocampus of TLR2-KO mice. These results are consistent with a role 
for TLR2 in inflammatory response following injury. However, neither 
TLR4-KO nor MyD88-KO mice showed a complete inhibition of behavioral 
hypersensitivity or axonal inflammation. It is thus possible that additional 
receptors or factors elicit neuroinflammation (Owens et al., 2005). 
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1.2.3.1. Alzheimer disease (AD) 
Aging is a physiological event often associated with a progressive increase 
in basal neuroinflammation state and innate immune receptor expression 
(Letiembre et al., 2009; Letiembre et al., 2007; Miller et al., 2007). It is 
not still clear why all these changes occur, although it may be an adaptive 
response to aging. Indeed, there is a correlation between the size of 
amyloid β (Aβ) plaques and the level of pro-inflammatory cytokines in the 
AD brain. Further, activated microglia surround and envelop the Aβ deposit, 
forming complexes between cell surface receptors such as CD36 and CD47, 
and Aβ (Bornemann et al., 2001; Bolmont et al., 2008). There is some 
evidence to suggest the involvement of TLRs in this complex formation. Aβ 
may trigger microglial TLR4-TLR6, releasing cytokines such as IL-1β, IL-10, 
IL-17 and TNF-α. Jin and colleagues (2008) have found a correlation 
between TLR4 signaling and AD progression. In another study, TLR2/TLR4-
double-KO mice receiving active Aβ immunization showed a reduction in 
pro-inflammatory mediator release and a less severe impairment of 
cognitive function (Vollmar et al., 2010). 
It is conceivable that TLRs have a dual role in the progression or 
attenuation of AD, which might be a function of the burden and biochemical 
composition of Aβ but also the extent of neuronal cell pathology (Hanke and 
Kelian, 2011). Whether or not TLRs may come forward as new potential 
therapeutic targets remains a speculative proposition. 
 
1.2.3.2. Multiple sclerosis  
Multiple sclerosis (MS) is a chronic neurodegenerative disease affecting 
brain and spinal cord and is characterized by autoimmune demyelination and 
progressive axonal degeneration (Hanke and Kelian, 2011). There is good 
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evidence to suggest that infections can provoke clinical relapses in MS 
patients (Sibley et al., 1985; Rapp et al., 1995; Buljevac et al., 2002). The 
best characterized PAMPs involved in these phenomena are PGN and 
pertussis toxin, which enable inappropriate immune-mediated recognition of 
self-antigens. As consequence antigen-presenting cells do not recognize 
self-myelin antigens. Molecular mechanisms are not completely clarified but 
probably involve TLRs on antigen-presenting cells (Segal et al., 2000; 
Ichikawa et al., 2002; Kerfoot et al., 2004; Waldner et al 2004; Visser et 
al., 2005). 
Experimental autoimmune encephalomyelitis (EAE) is the most common 
animal model for human MS. Pertussis toxin is necessary to induce the 
disease because of its ability to alter blood-brain barrier permeability to 
allow immune cell entry into the CNS (Racke et al., 2005). In this model the 
first effect is modulation of adhesion molecule (P-selectin)-dependent 
rolling of leukocytes to the cerebral vascular endothelium and blood-brain 
barrier impairment (Kerfoot et al., 2004). This cellular recruitment can be 
attenuated in TLR4-deficient mice. Although these data suggest TLR 
involvement, more experiments are needed. It may be possible that 
unknown environmental factors contribute to establishment of EAE in the 
animal model, given the observed variability in the study of Kerfoot et al., 
(2004). 
Human TLR4 genetic variants have been taken into consideration to 
determine disease involvement (Reindl et al., 2003; Kroner et al., 2005). 
Two mutations occur with high frequency: D299G, T399I. The former 
alters the TLR4 extracellular domain, resulting in defective signaling 
(Arbour et al., 2000; Lorenz et al., 2001). In MS patients the TLR4 
polymorphism does not appear to influence either incidence or progression 
 30 
 
of the pathology (Reindl et al., 2003; Kroner et al., 2005). In addition to 
TLR4, also TLR2 participates in the innate immune response in the EAE 
model. In some brain areas, levels of TLR2 expression are higher than 
those of TLR4 (Zekki et al., 2002). Accordingly, PGN can induce clinical 
disease (Visser et al., 2005). 
The above studies illustrate how TLRs can provide a link between infectious 
disease and uncontrolled immune response (Kelian et al., 2008). 
 
1.2.3.3. Spinal Cord injury 
Spinal cord injury (SCI) frequently occurs after motor/vehicle accidents, 
falls, sporting/recreation accidents and violence (Beers et al., 2006; 
Jackson et al., 2004). Spinal cord compression can result from traumatic 
SCI as well as non-traumatic events, such surgical intervention, tumor 
invasion or degenerative bone diseases (Prasad et al., 2005; Shedid et al., 
2007; Babb et al., 2006). During trauma, axon and myelin damage is delayed 
24-48 hours post-injury. Strategies to attenuate neurodegeneration have 
been oriented to blocking secondary injury cascades such ischemia, 
excitotoxicity and inflammation (Dusart et al., 1994; Fehlings et al., 2001). 
Injecting the TLR2 agonist zymosan into the spinal cord elicits production 
of neurotoxic mediators in the brain (Popovich et al., 2002). Several studies 
have demonstrated that TLR2, but not TLR4 causes significant axonal and 
myelin damage, even though the latter can induce macrophage activation 
(Schonberg et al., 2007). 
It is clear that TLRs influence SCI pathology and repair, post-traumatic 
inflammation, neuronal cell survival and axon regeneration. These receptors 
can be considered as potential targets for modulating SCI to facilitate 
reparative processes. Understanding how TLRs control neural and glial 
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progenitor cell fate will be critical in designing cell replacement therapies 
for SCI and other neurological disorders (Thuret et al., 2006; Bradbury et 
al., 2006). 
 
1.2.3.4. Neurogenesis, learning and memory 
Neural progenitor cells (NPSc) express many immune-relevant molecules 
necessary to interact with an inflamed CNS microenvironment (Ji et al., 
2004; Ni et al., 2004; Kim et al., 2006; Keohane et al., 2010; Ben-Hur et al., 
2003). Specific brain areas associated with the generation of new neurons 
are the sub-ventricular zone of the lateral ventricles and the sub-granular 
zone of the hippocampal dentate gyrus. Adult NPCs in these areas express 
TLR2 and TLR4 (Okun et al., 2010; Rolls et al., 2007). These PRRs control 
proliferation and differentiation of NPCs in opposing ways (Covacu et al., 
2009): TLR2-KO mice display impaired hippocampal neurogenesis whereas 
TLR4-KO animals show enhanced proliferation and neuronal cell 
differentiation. Like with TLR4-KO, TLR3-KO mice display increased 
hippocampal neurogenesis, hippocampal cornus hammonis 1 and dentate 
gyrus volumes (Okun et al., 2010). As these experiments were conducted in 
the absence of infectious stimuli, it remains unclear what signals are 
responsible for the observed phenotypes (Hanke and Kelian, 2011). Other 
physiological functions such as learning and memory can be related to TLR 
activation. Cognitive impairment is often associated with systemic 
inflammation (Cunningham et al., 2009), although the precise connection 
between TLRs and behavioral/cognitive functions remains to be elucidated 
(Hanke and Kelian, 2011). 
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2.THESIS AIMS 
 
In physiological conditions glia in the CNS can produce and release neuro-
protective factors such as anti-oxidants and neurotrophic factors 
(Sofroniew et al., 2010). Is not uncommon for the healthy brain to respond 
to stress and insults by transiently up-regulating inflammatory processes 
which are kept in check by endogenous protective elements (Carson et al., 
2006). Indeed, inflammation is fundamentally a protective cellular response 
aimed at removing injurious stimuli and initiating the healing process. When 
prolonged, however, inflammation overrides the bounds of physiological 
control and eventually becomes destructive. Upsetting this homeostatic 
balance, however, can result in disease or exacerbation of initiating factors 
that result in disease. Inflammation increasingly surfaces as a key element 
in the pathobiology of neurodegenerative diseases, stroke, spinal cord 
injury, neuropathic pain, and perhaps even neuropsychiatric disorders.   
From a mechanistic point of view, TLRs expressed by immunocompetent 
cells like microglia are thought to be critically involved in 
neuroinflammation. A number of questions remain open to investigation, 
including TLR expression by astrocytes (which are involved also in 
neuroinflammation) (Hanke and Kelian, 2011), cross-talk between microglia 
and astrocytes in inflammation, and the potential for activation of one TLR 
isoform to influence expression/activity of other TLR isoforms. 
This research project was organized around 3 main objectives: 
1. To establish and characterize cultures of microglia and astrocytes 
from neonatal rat cortex, utilizing immunocytochemical, molecular 
biological, and fluorescence-activated cell sorting techniques. This 
will include the application of methodology to purify astrocyte 
cultures, which will allow to observe their behaviors when presented 
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with and inflammatory challenge in the absence of contaminating 
microglia. 
2. To investigate how glia respond to TLR agonists through the analysis 
of TLR mRNA expression and their presence on cell surface 
(TLR2/4) or the endosome membrane (TLR3). 
3. To investigate the cross-talk mechanisms between glial cells in the 
CNS by: analyzing inflammatory mediator expression at the gene and 
product level in purified microglia, astrocyte-enriched cultures, and 
the effect of cultured microglia with purified astrocytes; 
establishing a “Transwell insert” system to examine the nature of 
interactions between the two types of glia, measuring the production 
of IL1β. 
 
35 
 
3. MATERIALS AND METHODS 
3.1. Primary culture of mixed glial cells 
Solutions: 
• Papain (Worthington (Lorne)) 
• DNAse I bovine pancreas 4 mg/mL (Sigma) 
• L-cysteine 24 mg/mL (Sigma) 
• Trypsin inhibitor 100 mg/mL (Sigma) 
• Bovine serum albumin 5 mg/mL (Sigma) 
• Poly-L-lysine 1 mg/mL in Borate Buffer 0.15 M pH 8.4 (Sigma) 
• L-leucyl-L-leucine methyl ester 50 mM (L-LME) (Sigma) 
 
Procedures: 
Mixed glial cell cultures were routinely prepared using postnatal day 1-2 rat 
pups of both sexes CD strain, Sprague-Dawley). Experiments were 
performed in accordance with the National Institutes of Health guidelines 
for the care and use of laboratory animals and those of the Italian Ministry 
of Health (D.L. 116/92), and were approved by the Institutional Animal Care 
and Use Committee. The cerebral hemispheres were removed and the 
meninges peeled off. The dissected cortical tissue was minced and 
incubated with a solution containing papain (140 µL), DNase I (30 µL) and L-
cysteine (30 µL) in L-15 medium (+L-glutamine, L-amino acids; Invitrogen) 
for 1 hour in a 37°C water bath. Upon completion of the enzyme incubation 
step the supernatant was replaced with ovomucoid solution (30 µL of 
tryspin inhibitor, 30 µL of DNase I and, 30 µL of bovine serum albumin in L-
15 medium) for 5 minutes at in a 37°C water bath. 
Cerebral cortices were plated in 75-cm2 poly-L-lysine-coated tissue culture 
flasks (BD Falcon) at a density of 1.5 brains per flask and grown in high-
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glucose Dulbecco’s modified Eagle’s medium (DMEM) (+4.5 g/L glucose, L-
glutamine, pyruvate; purchased from Invitrogen) with 2 mM glutamine, 50 
units/ml penicillin/ 50 µg/ml streptomycin, 50 µg/ml gentamycin and 10% 
fetal bovine serum (FBS) (glia growth medium). Culture medium was 
changed after 24 hours. 
 
3.1.1. Primary culture of purified microglial cells 
Rat microglia were isolated from the mixed glial cell cultures as previously 
described (Rosin et al., 2004). Microglia were isolated between days 7-10 
by shaking the flasks on an orbital shaker at 200 rpm for 1 hour (37°C). 
The culture supernatant (containing mainly microglia) was transferred to 
sterile petri plastic dishes (Sterilin, Bibby-Sarstedt) and incubated for 45 
minutes at 37°C (5% CO2, 95% air) to allow differential adhesion of 
microglia. The adherent microglial cells (>99% pure) were detached by 
mechanically scraping into glia growth medium and replated in this same 
medium, on poly-L-lysine-coated (10 µg/mL) microwell culture plates or 
dishes.  
 
3.1.2. Isolation of a purified population of astrocytes 
The attached cell monolayer remaining after shaking to recover microglia 
was used as a source of highly enriched astrocytes (>95%). To eliminate 
residual microglia, astrocyte monolayers were incubated 1 hour with 50 mM 
L-LME, a lysosomotropic agent (Hamby et al., 2006) dissolved in growth 
medium. Culture medium was exchanged for fresh medium, and allowed to 
recover for 1 day in growth medium prior to experimentation. Cultures were 
visually inspected to ensure microglial lysis. Care must be taken, as longer 
exposure times to L-LME can lead to astrocytic toxicity.  
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In some cases cell culture inserts were used to establish 
astrocyte/microglia co-cultures. Enriched astrocytes were seeded into a 
poly-L-lysine-coated 24-well plate (3 x 105 cells per well) in culture medium. 
Twenty-four hours later some cultures were treated with 50 mM L-LME 
for 60 minutes, as described above. In parallel, 24-well culture inserts 
were seeded with 5 x 104 microglia in culture medium (0.4 ml per insert), 
and placed in a 24-well plate (notched for inserts) in this same medium (0.8 
ml/well). Transwell cell culture inserts are convenient, easy-to-use 
permeable support devices; the suspended design allows for undamaged co-
culturing of cells in the lower compartment. The porous transwell membrane 
allows for communication between the chambers, and for passage of 
microglia-derived factors to the lower chamber containing astrocytes and 
vice versa. The following day, inserts were transferred to the 24-well plate 
of astrocytes. The distance between the astrocyte monolayer and microglia 
on the insert membrane is 1 mm, according to the manufacturer’s 
description. At this time LPS (100 ng/ml final) was added to either the 
upper or lower chamber (0.4 ml and 0.8 ml final volume, respectively), and 
incubation continued for another 24 hours. The culture medium was then 
collected, and cells lysed, as described below. The IL-1β content of culture 
supernatants and lysates was determined by ELISA, as described below. 
 
 
3.1.3. Treatment with TLR agonists 
Solutions: 
• LPS-EB Ultra-Pure 100 ng/mL (Invivogen) 
• Zymosan 10 µg/mL (Invivogen) 
• Poly(I:C) 50µg/mL (Sigma) 
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LPS-EB Ultra-Pure is a selective agonist for TLR4, zymosan binds TLR2 and 
poly(I:C) is a synthetic analogue of double stranded-RNA (dsRNA). 
Agonists were added in DMEM + 10% FBS. Cells were treated for 6 or 24 
hours for gene expression and cytofluorimetric analysis. For western blot 
analysis cells were treated in DMEM without serum for 15, 30 or 60 
minutes. After treatments cells were collected and processed as described 
in the following subsections. 
 
 
3.2 Immunophenotype analysis  
3.2.1 Flow Cytometry 
 
Solutions: 
• BD CytoFix/CytoPerm (BD Biosciences) 
• BD CytoFix (BD Biosciences) 
 
Procedures: 
The cortical cell suspension was fixed with BD CytoFix or 
fixed/permeabilized with BD CytoFix/CytoPerm at 4°C for 20 minutes. 
Purified microglia and enriched astrocytes were stained for flow 
cytometric analysis using different markers. The Immunophenotypical 
characterization was performed using the following antibodies:  
• mouse anti- GFAP (Cell Signaling) 
• rabbit anti-Iba1 (Wako) 
• rabbit anti-TLR2 (Santa Cruz) 
• rabbit anti-rat TLR4 (Santa Cruz) 
• rabbit anti-rat TLR3 (Santa Cruz) 
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For indirect staining, Alexa Fluor®488 anti-rabbit or anti-mouse secondary 
antibodies (Life Technologies) were utilized. Samples labelled with isotypic 
or secondary conjugated antibodies were prepared as controls. Data were 
acquired using a flow cytometer FACSCanto II (BD Biosciences) and then 
analyzed with the Substruction tool of Summit 4.3 software (DAKO-
Beckman Coulter). 
 
3.2.2 Immunofluorescence 
Solutions: 
• L-leucyl-L-leucine methyl ester 50 mM (L-LME) 
• Poly-L-lysine 1 mg/mL in borate buffer 0.15 M pH 
8.4 (Sigma) 
• 4 % paraformaldehyde (PFA) 
• Phosphate buffer saline (PBS) 10X 
NaCl 80 g 
KCl 1g 
Na2HPO4 5.75 g 
KH2PO4 1 g 
• 0.05%Triton-X 100 (0.05% PBS-T) 
• 10% Normal goat serum (NGS) 
• 4'-6'-diamidino-2-phenylindole (DAPI) 100 ng/ml 
• Fluoromount-G  
 
Procedures: 
Enriched astrocytes were seeded on poly-L-lysine-coated 12-mm diameter 
cover-glasses (Menzel-Gläser, Menzel GmbH, Germany) placed in the wells 
of a 12-well multiwall plate, at a density of 500,000 cells per well, using glia 
cell growth medium and allowed to adhere overnight. The next day the cells 
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were treated with 50 mM L-LME for 1 hour, and allowed to recover for 1 
day in growth medium. Cells were fixed with 4% PFA (Sigma-Aldrich), at 
4°C for 30 minutes. After fixation, cells were washed 3x10 minutes in PBS-
1X pH 7.4. Cells were then permeabilized and blocked with 0.05% PBS-T/ 
10% NGS for 1 hour at room temperature. Finally the cells were incubated 
overnight with primary antibody (Ab).  
The following Abs were used:  
- anti-GFAP (Sigma-Aldrich) for astrocytes  
- anti-Iba 1 (Wako, Japan) for microglia.  
Cells were washed with PBS-1X 3 times for 10 minutes and subsequently 
incubated for 1 hour at room temperature with an anti-mouse AlexaFluor 
595 or anti-rabbit Alexa Fluor488 Ab (1:500, Molecular Probes, Life 
Technologies). Nuclei where visualized by incubating for 2 minutes with 
DAPI (Boehringer Mannheim, Germany). Cover glasses were mounted onto 
glass slides using Fluoromount-G (Southern Biotech, USA), and images were 
acquired on a Leica DMI4000 B microscope equipped for 
immunofluorescence (Leica Microsystems GmbH, Wetzlar, Germany) using a 
Leica DFC 480 digital camera (Leica Microsystems GmbH, Wetzlar, 
Germany). 
 
3.3 Gene expression analysis and protein release 
Cells were seeded in poly-L-lysine-coated 24-well plates at a density of 
250,000 astrocytes per well and 25,000 microglia per well using glia cell 
growth medium. Cells were stimulated to produce and release pro-
inflammatory mediators using one of the following TLR agonist: LPS; 
Zymosan; Poly(I:C)) for 6 and 24 hours. Supernatants were collected for 
ELISA assay and cells were lysated for total RNA extraction.  
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3.3.1.Total RNA extraction  
Total RNA was isolated from cells using the ReliaPrep™ RNA Cell Miniprep 
System (Promega), according to the manufacturer’s instructions. Purity and 
integrity of the isolated RNA is critical for its effective use in applications 
such as reverse transcription PCR (RT-PCR) and reverse transcription 
quantitative PCR (RT-qPCR). In recent years, RT-PCR and RT-qPCR have 
emerged as powerful methods to identify and quantitate specific mRNAs 
from small amounts of total RNA and mRNA. The ReliaPrep™ RNA Cell 
Miniprep System has been designed to supply the need for methods to 
rapidly isolate high-quality RNA, substantially free of genomic DNA 
contamination, from small amounts of starting material. The ReliaPrep™ 
RNA Cell Miniprep System provides a fast and simple technique for 
preparing purified and intact total RNA from cultured cells. The system 
also incorporates a DNase treatment step designed to substantially reduce 
genomic DNA contamination, which can interfere with amplification-based 
methodologies.  
 
Solutions: 
 
• BL + TG Buffer 
4 M Guanidine thiocyanate 
0.01 M Tris (pH 7.5) 
2% 1-Thioglycerol 
• Column Wash Solution 
• DNase I incubation mix:  
24 µl of Yellow Core Buffer 
3 µl 0.09 M MnCl 
3 µl of DNase I enzyme 
• Yellow Core Buffer 
0.0225 M Tris (pH 7.5) 
1.125 M NaCl 
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0.0025% yellow dye (w/v) 
• RNA Wash Solution 
60 mM potassium acetate,  
10 mM Tris-HCl (pH7.5 at 25°C)  
60% ethanol 
 
• Nuclease-Free Water 
• 95% ethanol, RNase-free 
• 100% isopropanol, RNase-free 
• Phosphate buffer saline (PBS) 1X 
 
Lysates may be prepared directly in the culture dish by the addition of BL 
+ TG buffer directly to the dish for 5 minutes at room temperature to 
permit complete dissociation of nucleoprotein complexes. Cells lysates were 
collected in a sterile centrifuge tube and 100% isopropanol added (30 µL) 
and mixed by vortexing for 5 seconds. Lysates were then transfered to the 
ReliaPrep™ Minicolumn and placed into a collection tube (all provided by 
kit). The minicolumns with their bound nucleic acids were then centrifuged  
at 12,000 × g for 30 seconds at 20°–25°C. The binding reaction occurrs 
rapidly due to disruption of water molecules by the chaotropic salts, thus 
favoring adsorption of nucleic acids to the column, RNA wash solution 
(500µl) was then added to the minicolumn and the column centrifuged at 
12,000 × g for 30 seconds. To each miniclumn was applied 30 µl of freshly 
prepared DNase I incubation mix directly to the membrane inside the 
column and incubation carried out for 15 minutes at room temperature. This 
step allows for digestion of contaminating genomic DNA. After this 
incubation, column wash solution (200 µl) was added to the minicolumn to 
purify the bound total RNA from contaminating salts, proteins and cellular 
components. Samples were centrifuged at 12,000 × g for 15 seconds. RNA 
wash solution (500 µl) was added to the minicolumn and centrifuged at 
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12,000 × g for 30 seconds. This wash and centrifugation step was repeated 
again, but with 300 µL of column wash solution and a 2-minute spin at 
12,000 x g. The minicolumn was transferred to the elution tube, and 
nuclease-free water was added to the membrane (30 µL). Final elution was 
performed by centrifugation at 14,000 × g for 1 minute. The elution tube 
containing the purified RNA was store at –80°C until use.  
 
3.3.2. RNA spectrophotometric quantification  
Total RNA yield and purity was determined measuring 1 µL samples with the 
NanoDrop2000 spectrophotometer (Thermo Scinetific) at a wavelength of 
260 nm. 
Total RNA isolated with the ReliaPrep™ RNA Cell Miniprep System was 
substantially free of DNA and contaminating protein. The purity of the 
sample was evaluated by the determination of its optical density at 260 and 
230 nm, corresponding to the absorbtion wavelength of contaminants. The 
absorbance of RNA samples at 260 nm and 280 nm, diluted in nuclease-free 
water, was used to evaluate protein contamination (A260/A280 ratio). Pure 
RNA exhibits a A260/A280 ratio of 2.0. 
However, it should be noted that, due to variations between individual 
starting materials and in performing the procedure, the expected range of 
A260/A280 ratios for RNA may be 1.7–2.1. Using this protocol, the RNA 
usually exhibited an A 260/A230 ratio of 1.8-2.2. A low A260/230 may 
indicate guanidine contamination that can interfere with downstream 
processing. 
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3.3.3. First-Strand cDNA Synthesis  
Retrotranscription (RT) reaction mixture was prepared in a final volume of 
10 µl.  
 
Mix components Qty 
random primers 250 ng 
dNTP Mix   5 mM 
Total RNA 5 µg 
 
 
The mixture was heated to 65°C for 5 minutes and incubated on ice for at 
least 1 minute for primer annealing. The reaction was performed adding in 
the tubes: 
 
First-Strand Buffer 5X 
Dithiothreitol (DTT) 0.1 M 
RNase OUT Recombinant Ribonuclease Inhibitor  40 U/mL 
SuperScript™ III Reverse Transcriptase (200 U/mL). 
 
 
RT reaction was performed at 50°C for 70 minutes and inactivated by 
heating at 75°C for 15 minutes. The cDNA was stored at -20°C until use. 
 
 
 
3.3.4. Real Time-Polymerase Chain Reaction (qRT-PCR)  
 
3.3.4.1. Primer design 
One of the most important steps in selective amplification of a cDNA 
target is primer design. Nowadays many tools are available on-line. For our 
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experiments, primers were designed on-line on www.pubmed.com using 
“Primer-BLAST”. Forward primer (For) binds the Leader strand of double-
stranded DNA while reverse primer (Rev) binds the Lagging strand of 
double-stranded DNA. 
 
The following primer pairs were used: 
 
Gene Target Primer Name Sequence 
GAPDH GAPDH   For 5'-CAAGGTCATCCATGACAACTTTG-3’ 
GAPDH   Rev 5'-GGGCCATCCACAGTCTTCTG-3’ 
IL-1ß 
IL-1ß For 5’-TGTGGCAGCTACCTATGTCT-3’  
IL-1ß   Rev 5’-GGGAACATCACACACTAGCA-3’ 
TNF-α 
TNF-a For 5’-CATCTTCTCAAAACTCGAGTGACAA-3’  
TNF-a Rev 5’-TGGGAGTAGATAAGGTACAGCCC-3’ 
IL-6 
IL-6 For 5’-TCACAGAAGGAGTGGCTAAGG-3’ 
IL-6 Rev 5’-GCTTAGGCATAGCACACTAGG-3’ 
TLR2 
TLR2 For 5’-TCCATGTCCTGGTTGACTGG-3’ 
TLR2 Rev 5’-AGGAGAAGGGCACAGCAGAC-3’ 
TLR 4 
TLR4 For 5’-GATTGCTCAGACATGGCAGTTTC-3’ 
TLR4 Rev 5’-CACTCGAGGTAGGTGTTTCTGCTAA-3’ 
TLR 3 
TLR3 For 5’-TGAAAACTACGGCGATGCAG-3’ 
TLR3 Rev 5’-AGGCAGTTTTACTTCCCCGA-3’ 
 
 
 
 
3.3.4.2. qRT-PCR analysis 
Total RNA was extracted from cells using the ReliaPrep™ RNA Cell 
Miniprep System (Promega), according to the manufacturer’s instructions. 
RT was performed with Superscript III reverse transcriptase (Life 
Technologies). The qRT-PCR is a real time PCR reaction, performed in a MX 
3000P, Stratagene. 
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The PCR cycling conditions were 4 minutes of denaturation followed by 50 
cycles of: 
 
 Temp (°) Time (sec) 
Annealing 94 30 
Denaturation 60 30 
Elongation 72 30 
 
 
At the end of the amplification there was a dissociation thermal profile of 
95°C for 1 minute, 55°C for 30 seconds, and 95°C for 30 seconds. Amounts 
of each gene product were calculated using linear regression analysis from 
standard curves, demonstrating amplification efficiencies ranging from 90 
to 100%. Dissociation curves were generated for each primer pair showing 
single product amplification. 
 
3.3.4.3. Statistical analysis 
Data are given as mean ± SEM. Statistical analyses to determine group 
differences were performed either by two-sample equal variance Student’s 
t test, or by one-way analysis of variance, followed by Dunnett’s or 
Mix components Volume (µL) 
SYBR green JumpStart Taq ReadyMix 2X  5 
Internal Reference (Rox) 100X 0.1 
Forward primer 100 nM 0.1 
Reverse Primer 100 nM 0.1 
H2O 4.2 
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Bonferroni’s post-hoc tests for comparisons involving more than two data 
groups. Significance was taken at p<0.05. 
 
3.3.5 Protein expression analysis 
3.3.5.1. Total protein extraction  
Solutions: 
• NP40 Lysis Buffer (Invitrogen) 
50 mM Tris, pH 7.4 
250 mM NaCl 
5 mM EDTA 
50 mM NaF 
1 mM Na3VO4  
1% Nonidet P40 (NP40) 
0.02% NaN3 
• Proteinase inhibitor cocktail (Sigma) 
• Pefablock 0.1 M (Roche) 
• Working solution 
NP40 lysis buffer 
Proteinase inhibitor cocktail 1:10 
Pefablock 0.1 M 1:100 
Cell lysis with mild detergent is commonly used for cultured animal cells. 
Working solution was added for 30 minutes to adherent cells (on ice) and 
then the extract was transferred to a centrifuge tube. Lysates were 
centrifuged at 12,000 x g for 10 minutes at 4°C. After centrifugation, the 
supernatant was collected and stored at -80°C until use for protein 
determination and western blot analysis. 
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3.3.5.2. Western blot analysis 
Protein quantification was conducted using the BCA Protein Assay Reagent 
Kit (Pierce) according to the manufacturer’s protocol. Protein samples (10 
µg) were separated on a Mini-PROTEAN ® Precast Gel (Biorad) with a 4-
15% gradient for 90 minutes at 140V. Proteins were electrophoretically 
transferred from the gel onto polyvinylidene difluoride (PVDF, Millipore) 
membranes overnight at 4°C at 25V. Membranes were blocked with 3% 
bovine serum albumin (Sigma Aldrich) and then incubated overnight at 4°C 
with one of the following primary antibodies: 
GAPDH (working dilution 1:200; Santa Cruz) 
β-Actin (working dilution 1:25000; Sigma) 
TLR4 (working dilution 1:300; Abcam) 
CD14 (working dilution 1:200; Santa Cruz) 
MD2 (working dilution 1:1000; Abcam) 
 
The membranes were washed and then incubated for 1 hour with the 
appropriate secondary antibody (goat anti-rabbit or goat anti-mouse, 
BioRad) conjugated to horseradish peroxidase (HRP) at a dilution of 1:4000. 
Developing has been performed using an enhanced chemiluminescence 
substrate (Sigma). Immunreactivity was visualized using the VersaDoc 
Imaging System and protein expression normalized to GAPDH or β-actin 
for band density quantification. 
 
3.3.6 Cytokine enzyme-linked immunosorbent assay (ELISA) 
Solutions: 
 Coating antibody working solution 
Coating antibody stock solution (1:100) 
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Coating buffer 
 Detection antibody working solution 
Detection antibody stock (1:200) 
Assay diluent 
 Avidin-HRP working solution 
Avidin-HRP stock solution (1:2000) 
Assay diluent 
 Color development solution 
Color development Reagent A:B (1:2) 
 Stop solution 
H2SO4 (2 M) 
 PBS-T 
PBS 
Tween-20 (1:2000) 
 
Procedure: 
Cells were seeded in poly-L-lysine-coated 24-well plates at a density of 
250,000 astrocytes per well and 25,000 microglia per well using glia cell 
growth medium. Cells were stimulated to produce and release pro-
inflammatory mediators in medium containing TLR agonist (LPS; Zymosan; 
Poly(I:C)). Cell supernatants were harvested after 24 hours and cytokine 
release was assayed by ELISA according to the manufacturer’s instructions 
(Antigenix America, Huntington Station, NY, USA). 
Multi-well plates were pre-coated with coating antibody working solution.  
Supernatants were incubated in these pre-coated multi-well plates at room 
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temperature for 2 hours and then washed using PBS-T. Detection antibody 
working solution was added to the plates and incubation continued for 
another 2 hours. After washing, Avidin-HRP working solution was added, 
the plated were incubated at room temperature for 30 minutes, followed 
by addition of color development solution. After a futher 30-minute 
incubation the reaction was stopped by adding 2N H2SO4 and absorbance 
measured at a wavelength of 540 nm. The amount of cytokine was 
quantified using a standard curve. 
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4. RESULTS 
PART 1 
4.1 Cellular and molecular characterization of glial cell populations from 
cortex 
4.1.1. Immuno-phenotypic characterization  
Glial cell preparations were subjected to flow cytometric analysis to 
determine expression of cell type-specific (astrocytes and microglia) 
surface markers by immunoreactivity. Cells were defined by cell count 
versus GFAP expression level (Fig. 4.1, first column), by granularity 
characteristics (side scatter, SSC) versus Iba1 expression level (Fig. 4.1, 
second column) and finally by size (forward scatter, FSC) versus 
granularity (SSC) (Fig. 4.1, third column). The basic scatter dot blot was 
used to exclude cell debris from the analysis and the regions containing 
astrocytes and microglia were identified. By gating the individual 
subpopulation (determined by GFAP expression, low or high), the level of 
Iba1 expression was examined. 
In the mixed glial cell population, GFAP-negative staining corresponds to 
microglia. Microglia (defined as GFAP-negative cells) can be also 
morphologically identified as the smaller cells and with less surface 
complexity compared to the GFAP-positive subpopulation (Fig. 4.1, row A). 
The percentage of these two cell groups are about 90% GFAP+ and 10% 
GFAP-. 
In the CNS microglia comprise 5-20% of all glial cells, depending on the 
specific brain region (Sajo and Glas, 2011; Lawson et al., 1990). Our 
characterization confirms data available in the literature. This mixed glial 
cell population can be used as a starting point for the isolation of purified 
microglia and astrocyte-enriched subpopulations. 
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Purified microglia were obtained by detaching this population from the 
starting mixed glial cell preparation, as described in “Materials and 
Methods”. Iba1 staining in back-gating analysis is shown in dot blot graphs 
(fig. 4.1, row B, middle and right panels). These results confirm the isolation 
of a population with essentially 100% of cells expressing Iba1. 
Astrocyte-enriched cultures were immunostained for GFAP (Fig. 4.1, row C). 
By gating on GFAP expression (as for the mixed cell preparation) we 
obtained 95% GFAP-positive cells; the remaining 5% of GFAP-negative cells 
correspond to microglial cell contamination. 
 
Fig. 4.1. Flow cytometric analysis of glial cell cultures with cell-type 
specific markers. Analysis of mixed glial cell cultures shows that Iba1-
positive cells (microglia-specific marker) correspond to about 10% of all 
the events recorded GFAP-positive cells (astrocyte-specific marker) 
represent the most abundant population in the sample (row A). Analysis of 
purified microglia shows that Iba1-positive cells comprise essentially 100% 
of events recorded; there is no signal for the astrocyte marker GFAP (row 
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B). Analysis of enriched astrocyte cultures shows that GFAP-positive cells 
represent 95% of all events recorded (row C). 
 
4.1.2. Morphological and molecular characterization of astrocyte-
enriched and purified cultures 
The above-descibed astrocyte-enriched cultures (≥95%) were next 
subjected to analysis by indirect immunofluorescence using cell-type 
specific antibodies. Astrocytes were again identified by their expression of 
GFAP, while microglia were immunostained with Iba-1 (Fig. 4.2, upper row). 
In order to study astrocyte behaviors without potential interference from 
contaminating microglia, L-LME was used to deplete cultures of residual 
microglia. L-LME is a lysosomotropic agent which enters cells via receptor-
mediated endocytosis. L-LME undergoes a condensation process catalyzed 
by dipeptidyl peptidase I, also known as cathepsin C (Thiele and Lipsky, 
1990) in lysosomes. Condensation of L-LME leads to lysosomal rupture and 
DNA fragmentation in dipeptidyl peptidase I-expressing immune cells, like 
microglia. 
L-LME was employed initially to destroy macrophages (Thiele et al., 1983) 
and, more recently, to deplete microglia from neural cultures including 
astrocytes (Giulian et al., 1993; Guillemin et al., 1987) and oligodendrocytes 
(Hewett et al., 1999). Hamby et al. (2006) demonstrated that exposing 
confluent cortical astrocytes to 50-75 mM L-LME  for  60-90  minutes  
effectively  depleted  microglia  from  the  high-density  astrocyte 
monolayers, as evidenced by the selective depletion of microglial-specific 
markers. The resulting purified astrocyte monolayers appeared 
morphologically normal 24 hours after L-LME treatment.  
To verify the effect of L-LME treatment in our cultures, enriched cortical 
astrocytes were first incubated 60 minutes with 50 mM L-LME, and then 
processed for immunofluorescence analysis and Iba-1 gene expression by 
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RT-PCR. Immunostaining of these cortical astrocytes shows a confluent 
carpet of GFAP+ cells, interspersed with a few Iba1+ immunoreactive cells 
(Fig. 4.2, lower row); the resulting astrocyte purity was judged to be ≥99%. 
 
 
Fig. 4.2. Cortical astrocyte-enriched cultures were characterized by immunostaining using 
GFAP (red) for astrocytes and Iba1 (green) for microglia (Upper panels). L-LME treatment 
reduces markedly Iba1-positive microglia while GFAP-positive astrocytes remain abundant 
(lower panels). In these images, nuclei are colored blue with DAPI, which forms 
fluorescent complexes with natural double-stranded DNA. 
 
Microglia but not astrocytes are reported to express the mRNA for Iba-1. 
Indeed, elimination of residual microglia from the L-LME-treated enriched 
astrocyte cultures was confirmed by the loss of Iba-1 gene expression (Fig. 
4.3). For all Real Time-PCR analyses, the amount of gene product was 
calculated using linear regression analysis from standard curves, 
demonstrating amplification efficiencies ranging from 90%-100%. The term 
“fold-increase” is defined as the cDNA ratio between target gene and 
reference gene (GAPDH) normalized to untreated control.  
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Fig. 4.3. Astrocyte cultures were characterized by Iba1 
mRNA levels. L-LME treatment in a purified-astrocyte 
culture (≥99%) leads Iba1 mRNA level to a 0.17-fold 
difference compared to control (enriched-astrocyte 
culture, ≥95%). 
 
 
 
PART 2 
 
4.2 TLR agonist-dependent pro-inflammatory profile in purified 
microglia 
4.2.1 Cytokine gene expression modulation after LPS, zymosan and 
poly(I:C) treatment  
Microglia are the brain’s macrophages which serve specific functions in 
defense of the CNS against microorganisms, removal of tissue debris in 
neurodegenerative diseases or during normal development, and in 
autoimmune inflammatory disorders of the brain (Zielasek and Hartung, 
1996). Microglia express functional TLR2 (Kim et al., 2007) and TLR3 (Ribes 
et al., 2010; Obata et al., 2008) in addition to TLR4. TLR signalling 
pathways may be involved in neurodegenerative disorders (Okun et al., 
2011). 
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In cultured microglia, soluble inflammatory mediators such as cytokines and 
bacterial products like LPS are capable of inducing a wide range of 
microglial cell activities, e.g. increased phagocytosis, chemotaxis, secretion 
of cytokines, activation of the respiratory burst and induction of nitric 
oxide synthase (Zielasek and Hartung, 1996).  
Given the complexity of studying glial cell activation in vivo, for these 
experiments we used well-characterized cultures of purified microglia to 
examine their responses to zymosan (TLR2 activator) (Ozinsky et al., 2000) 
and poly(I:C), an activator of TLR3 (Alexopoulou et al., 2001). Commercial 
sources of LPS are frequently contaminated by other bacterial components, 
such as lipoproteins, thus activating TLR2 as well as TLR4 signalling. The 
Ultra-Pure LPS-EB preparation used here (referred to as ‘LPS’) only 
activates the TLR4 pathway (InvivoGen). 
As reported in the following figures, engagement of each of the three 
TLRs resulted in IL-1β, IL6 and TNF-α gene induction. 
In all cases, the fold-difference in the level of normalized gene target in 
treated cells is expressed relative to control samples (CTR) and reported 
as mean ± standard error (SEM) where CTR is equal to 1. 
Cultures were stimulated with 100 ng/ml of LPS for 6 and 24 hours. IL-1β, 
IL-6 and TNF-α transcripts are up-regulated after treatment versus 
control. mRNAs show a peak induction at 6 hours of treatment (277.37 ± 
26.67 vs CTR ± 0.29 for IL-1β; 79.01 ± 7.44  vs CTR ± 0.24 for IL-6; 11.67 ± 
1.31 vs CTR ± 0.21 for TNF-α). At 24 hours all three mRNAs are still up-
regulated (170.91 ± 6.97 vs CTR ± 0.12 for IL-1β; 64.67 ± 5.08 vs CTR ± 
0.42 for IL-6; 8.38 ± 1.11 vs CTR ± 0.14 for TNF-α) (Fig. 4.4). 
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Fig. 4.4 Purified microglia were challenged with LPS (100 ng/ml) 
and processed for mRNA expression by RT-PCR. IL-1β, IL-6 and 
TNF-α mRNA were quantified after 6 hours (left panels) and 24 
hours (right panels) of treatment.  Data are means ± SEM 
(triplicate culture wells) normalized to GAPDH levels, and are 
representative of 3 experiments. Statistical significance, 
calculated by Dunnett’s multiple comparision test vs untreated 
cells: p≤0.05*; p≤0.01**; p≤0.001*** 
 
 
Moreover, cultures were stimulated with 10 µg/ml of zymosan for 6 and 24 
hours. mRNAs for IL-1β, IL-6 and TNF-α are up-regulated after treatment 
versus control (1874.46 ± 111.08 vs CTR ± 0.06 for IL-1β; 134.57 ± 7.31 vs 
CTR ± 0.42 for IL-6; 91.53 ± 7.78 vs CTR ± 0.15 for TNF-α).  
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At 24 hours all three mRNAs are still up-regulated (180.48 ± 14.40 vs CTR 
± 0.31 for IL-1β; 40.29 ± 7.17vs CTR ± 0.29 for IL-6; 7.82 ± 1.23 vs CTR ± 
0.24 for TNF-α) (Fig. 4.5). 
 
Fig. 4.5 Purified microglia were challenged with zymosan (10 µg/ml) and 
processed for mRNA expression by RT-PCR. IL-1β, IL-6 and TNF-α 
mRNA were quantified after 6 hours (left panels) and 24 hours (right 
panels) of treatment. Data are means ± SEM (triplicate culture wells) 
normalized to GAPDH levels, and are representative of 3 experiments. 
Statistical significance, calculated by Dunnett’s multiple comparison test 
vs untreated cells: p≤0.05*; p≤0.01**; p≤0.001*** 
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Finally, cultures were stimulated with 50 µg/ml of poly(I:C) for 6 and 24 
hours. mRNAs for IL-1β, IL-6 and TNF-α are up-regulated after treatment 
versus control (563.91 ± 49.36 vs CTR ± 0.27 for IL-1β; 90.02 ± 16.36 vs 
CTR ± 0.44 for IL-6; 34.55 ± 3.05  vs CTR ± 0.06 for TNF-α).  
At 24 hours all three mRNAs remain up-regulated (108.31 ± 11.18 vs CTR ± 
0.06 for IL-1β; 78.40 ± 25.04 vs CTR ± 0.39 for IL-6; 6.79 ± 2.39 vs 
CTR ± 0.10 for TNF-α) (Fig. 4.6). 
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Fig. 4.6 Purified microglia were challenged with poly(I:C) (50 µg/ml) 
and processed for mRNA expression by RT-PCR. IL-1β, IL-6 and 
TNF-α mRNA were quantified after 6 hours (left panels) and 24 
hours (right panels) of treatment. Data are means ± SEM 
(triplicate culture wells) normalized to GAPDH levels, and are 
representative of 3 experiments. Statistical significance, 
calculated by Dunnett’s multiple comparision test vs untreated 
cells: p≤0.05*; p≤0.01**; p≤0.001*** 
 
 
4.2.2. IL-1β release after LPS, zymosan and poly(I:C) treatment 
In the brain, IL-1β is mainly produced by activated microglia (Giulian et al., 
1986; Van Dam et al., 1995). LPS is a potent activator of IL-1β 
transcription/translation (Chauvet et al., 2001) and this process occurs in 
primary cortical microglia, as well (Barbierato et al., 2013).  
Our experiments suggest that not only LPS but also treatment with other 
TLR ligands causes appreciable amounts of IL-1β to accumulate in the 
culture medium after 24 hours. In particular, LPS induces synthesis and 
release of 32.54 ± 10.01 pg/mL, zymosan induces 95.85 ± 6.55 pg/mL and 
poly(I:C) induces 84.81 ± 3.24 pg/mL of IL-1β (Fig. 4.7). 
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Fig. 4.7 Purified microglia were challenged with 
agonists of TLR2, -3 and -4 and processed for protein 
measurement by ELISA. Supernatants were collected 
and IL-1β quantified after 24 hours of treatment. 
Standards with known amounts of IL-1β were used to 
convert values into absolute concentration of IL-1β in 
pg/mL. Data are means ± SEM (triplicate culture wells). 
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4.2.3. TLR gene expression and protein modulation 
4.2.3.1 TLR modulation in microglia challenged with LPS 
TLR4 is expressed in a number of tissues, and is particularly pronounced 
among myelomonocytic cells (Munzio et al., 2000; Poltorak et al., 1998). 
Munzio et al. (2000) reported that LPS increased levels of TLR4 mRNA in 
human peripheral blood monocytes in an actinomycin D-dependent fashion, 
suggesting a transcriptional regulation. By contrast, Poltorak et al. (1998) 
demonstrated that TLR4 mRNA was constitutively expressed in RAW 264.7 
macrophage cells, being rapidly and transiently suppressed by LPS 
treatment. Similarly, Nomura et al. (2000) observed that LPS treatment of 
mouse peritoneal macrophages lowered both TLR4 mRNA levels and surface 
TLR4 expression (Fan et al., 2014). 
As TLR4 regulation in glia remains largely unexplored, we focused on gene 
expression analysis of TLRs in microglia challenged with 100 ng/mL LPS for 
6 and 24 hours. After 6 hours of treatment, TLR4 mRNA level was 
significantly down-regulated versus control (0.10 ± 0.04 vs CTR ± 0.32) (Fig. 
4.8A, top left panel) and the effect prolonged until 24 hours (0.42 ± 0.01  
vs CTR ±  0.03) (Fig. 4.8A, top right panel). Unexpected, LPS modulates also 
TLR2, but rather inducing a strong up-regulation after both 6 hours (3.93 ± 
0.37 vs CTR ±  0.20) (Fig. 4.8A, middle left panel) and 24 hours (2.28 ± 0.03 
vs CTR ±  0.02) (Fig. 4.8A, middle right panel). Although TLR3 mRNA level 
did not change after 6 hours of LPS treatment (0.87 ± 0.07 vs CTR ± 0.07) 
(Fig. 4.8A, bottom left panel) a highly significant down-regulation was 
observed after 24 hours (0.26 ± 0.01 vs CTR ± 0.07) (Fig. 4.8A, bottom 
right panel).  
The expression of TLR protein level was studied using flow cytometric 
analysis, identifying the percentage of positive cells and Mean Fluorescent 
Intensity (MFI). This parameter is closely related to the amount of 
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antibody bound to a specific target protein, in particular TLRs. The aim was 
to evaluate both the early (1 hour) effect of TLR ligand on the protein 
complex and the effect of prolonged exposure (samples analysis  
performed after 6 and 24 hours). The percentage of TLR labelled cells 
progressively decreased and MFI resulted significantly down-regulated 
(Fig. 4.8B). 
 
Fig. 4.8A. Effects of LPS on TLR gene expression in purified rat 
cortical microglia. TLR mRNA levels were evaluated by Real-Time 
PCR after 6 and 24 hours of treatment. Data are means ± SEM 
(triplicate culture wells) normalized to GAPDH levels, and are 
representative of 3 experiments. Statistical significance, 
calculated by Dunnett’s multiple comparision test vs untreated 
cells: p≤0.05*; p≤0.01**; p≤0.001*** 
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Fig. 4.8B. TLR expression in rat cortical microglia challenged with LPS: analysis by flow 
cytometry. Microglia were challenged with 100 ng/mL LPS for 1, 6 and 24 hours. Data 
reported in histograms are expressed as percentage of positive cells (red profiles) with 
respect to controls (grey profiles) prepared using secondary antibodies. Bar chart graphs 
represent the relative MFI measured on the sample. Data are means ± SEM (duplicate 
culture wells) normalized to secondary antibody MFI. Statistical significance, calculated 
by Dunnett’s multiple comparision test vs untreated cells: p≤0.05*; p≤0.01**; p≤0.001*** 
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4.2.3.2. TLR modulation in microglia challenged with zymosan 
TLR gene expression was next analysed in microglia challenged with 10 
µg/mL zymosan for 6 and 24 hours. As expected, zymosan modulates its 
target receptor, TLR2, inducing a marked and significant up-regulation 
after 6 hours (7.52 ± 1.00 vs CTR ± 0.04) (Fig. 4.9A, middle left panel) 
which persisted up to at least 24 hours (2.60 ± 0.39 vs CTR ± 0.09) (Fig. 
4.9A, middle right panel). 
TLR2 agonist activity regulates also TLR4 and TLR3 mRNA. Transcript 
levels for TLR4 are significantly down-regulated versus control at both 6 
hours (0.26 ± 0.07 vs CTR ± 0.03) (Fig. 4.9A, top left panel) and 24 hours 
(0.33 ± 0 .05 vs CTR ± 0.24) (Fig. 4.9A, top right panel). Likewise, TLR3 
mRNA experiences a significant reduction 6 hours (0.43 ± 0.03 vs CTR ± 
0.10) (Fig. 4.9A, bottom left panel) and 24 hours (0.24 ± 0.05  vs CTR ± 
0.14) (Fig. 4.9A, bottom right panel) with LPS treatment. 
In terms of TLR protein expression, flow cytometric analysis showed that 
the percentage of positive cells marked for TLR2 is not influenced by 
zymosan treatment, as confirmed by MFI, while TLR3 is progressively 
increased. TLR4 expression on the cell surface, as for TLR2, is not altered 
by zymosan treatment (Fig. 4.9B). 
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Fig. 4.9A. Effects of zymosan on TLR gene expression in purified rat cortical 
microglia. TLR mRNA levels were evaluated by Real-Time PCR after 6 and 24 hours 
of treatment. Data are means ± SEM (triplicate culture wells) normalized to 
GAPDH levels, and are representative of 3 experiments. Statistical significance, 
calculated by Dunnett’s multiple comparision test vs untreated cells: p≤0.05*; 
p≤0.01**; p≤0.001*** 
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Fig. 4.9B. TLR expression in rat cortical microglia challenged with zymosan: analysis by 
flow cytometry. Data reported in histograms are expressed as percentage of positive 
cells (red profiles) with respect to controls (grey profiles) prepared using secondary 
antibodies. Bar chart graphs represent the relative MFI measured on the samples. 
Data are means ± SEM (duplicate culture wells) normalized to secondary antibody MFI. 
Statistical significance, calculated by Dunnett’s multiple comparision test vs untreated 
cells: p≤0.05*; p≤0.01**; p≤0.001*** 
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4.2.3.3. TLRs modulation in microglia challenged with poly(I:C) 
Gene expression analysis of TLRs in microglia challenged with 50 µg/mL 
poly(I:C) for 6 and 24 hours was analysed. Unexpected, poly(I:C) does not 
modulate its target receptor, TLR3. A trend to decrease after 24 hours 
was observed, but was not statistically significant (6 hours treatment: 0.97 
± 0,03 vs CTR ± 0.14; 24 hours treatment: 0.65 ± 0.18 vs CTR ± 0.10) (Fig. 
4.10A, bottom left and right panels). Poly(I:C), however, induced a highly 
significant increase in TLR2 gene expression after 6 hours (5.32 ± 0.42 vs 
CTR ± 0.14) and 24 hours (2.83 ± 0.73 vs CTR ± 0.08) (Fig. 4.10A, middle 
left and right panels, repectively). Transcript levels for TLR4 showed a 
statistically significant down-regulation after 6 hours (0.11 ± 0.01 vs CTR ± 
0.14) (Fig. 4.10A, top left panel) and a non-significant trend after 24 hours 
(0.68 ± 0.22 vs CTR ± 0.10) (Fig. 4.10A, right column).  
Flow cytometry revealed that poly(I:C) increased its target receptor, 
TLR3, after 1 hour. The percentage of positive cells for all 3 TLRs was 
significantly diminished after both 6 and 24 hours exposure to poly(I:C). 
These data were confirmed by MFI (Fig. 4.10B). 
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Fig. 4.10A. Effects of poly(I:C) on TLR gene expression in purified rat 
cortical microglia. TLR mRNA levels were evaluated by Real-Time PCR 
after 6 and 24 hours of treatment. Data are means ± SEM (triplicate 
culture wells) normalized to GAPDH levels, and are representative of 3 
experiments. Statistical significance, calculated by Dunnett’s multiple 
comparision test vs untreated cells: p≤0.05*; p≤0.01**; p≤0.001*** 
 
 70 
 
 
Fig. 4.10B. TLR expression in rat cortical microglia challenged with 50 µg/mL poly(I:C) for 
1, 6 and 24 hours: analysis by flow cytometry. Data reported in histograms are expressed 
as percentage of positive cells (red profiles) with respect to controls (grey profiles) 
prepared using secondary antibodies. Bar chart graphs represent the relative MFI 
measured on the samples. Data are means ± SEM (duplicate culture wells) normalized to 
secondary antibody MFI. Statistical significance, calculated by Dunnett’s multiple 
comparision test vs untreated cells: p≤0.05*; p≤0.01**; p≤0.001*** 
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PART 3 
4.3. TLR agonist-dependent cytokine expression in astrocytes: 
influence of microglia 
Numerous studies have described the use of astrocyte-enriched cultures 
to study their capability to elaborate inflammation-related molecules, e.g. 
cytokines, chemokines, and adhesion molecules. Oftentimes these reports 
assume that astrocytes are the cell type responsible for the observed 
effect, although this point can be questioned (Saura, 2007).   
In view of the above, we decided to more fully characterize the role of 
astrocytes in our cultures, using a specific microglia toxin, L-LME (Thiele et 
al., 1983) to eradicate residual microglia. Confluent enriched astrocyte 
monolayers were treated for 1 hour with 50 mM L-LME (Hamby et al., 
2006) followed 24 hours later by challenge with TLR ligands. As shown 
earlier, enriched astrocytes strongly respond to LPS (Fig. 4.11), zymosan 
(Fig. 4.12) and poly(I:C) (Fig. 4.13) treatment after both 6 and 24 hours 
with up-regulation of mRNA for the pro-flammatory cytokines IL-1, IL-6 
and TNF-. Under these conditions, we verified that L-LME-treated 
astrocytes were unable to respond to the TLR ligands with induction of IL-
1β and IL-6 mRNA expression, although TNF-α gene expression is not 
completely abolished (Figs. 4.11, 4.12, 4.13). 
These observations are consistent with earlier findings (Barbierato et al., 
2013). Because nominally microglia-free astrocytes are incapable of 
producing pro-inflammatory mediators following TLR2/3/4 activation, it is 
not unreasonable to assume that astrocytes per se are not the source of 
these molecules during inflammation.   
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Fig. 4.11 Responsiveness of enriched astrocytes to LPS (100 ng/ml) 
challenge before and after removel of microglia with L-LME: analysis 
of IL-1β, IL-6 and TNF-α mRNA expression by RT-PCR. Cells were 
processed after 6 hours (left column) and 24 hours (right column) of 
treatment. Data are means ± SEM (triplicate culture wells) 
normalized to GAPDH levels, and are representative of 3 
experiments. Statistical significance, calculated by Dunnett’s 
multiple comparision test vs untreated cells: p≤0.05*; p≤0.01**; 
p≤0.001*** 
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Fig. 4.12 Responsiveness of enriched astrocytes to zymosan (10 
µg/ml) challenge before and after removel of microglia with L-LME: 
analysis of IL-1β, IL-6 and TNF-α mRNA expression by RT-PCR. 
Cells were processed after 6 hours (left column) and 24 hours 
(right column) of treatment. Data are means ± SEM (triplicate 
culture wells) normalized to GAPDH levels, and are representative 
of 3 experiments. Statistical significance, calculated by Dunnett’s 
multiple comparision test vs untreated cells: p≤0.05*; p≤0.01**; 
p≤0.001*** 
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Fig. 4.13 Responsiveness of enriched astrocytes to poly(I:C) (50 µg/ml) 
challenge before and after removal of microglia with L-LME: analysis of IL-
1β, IL-6 and TNF-α mRNA by RT-PCR. Cells were processed after 6 hours 
(left column) and 24 hours (right column) of treatment. Data are means ± 
SEM (triplicate culture wells) normalized to GAPDH levels, and are 
representative of 3 experiments. Statistical significance, calculated by 
Dunnett’s multiple comparision test vs untreated cells: p≤0.05*; p≤0.01**; 
p≤0.001*** 
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4.4. LPS binding to TLR4 
TLR4 is currently the best-characterized TLR. Together with MD2 and 
CD14, TLR4 forms a complex that binds LPS (Shimazu et al., 1999; 
Viriyakosol et al., 2000). Microglia express TLR4 on their cell surface 
(Kitamuraet al., 2001; Qin et al., 2005) and CD14, as demonstrated using 
primary microglia from CD14 KO mice (Esen and Kelian, 2005). Together 
MD2 and CD14 interact with TLR4 to maximize LPS responsiveness.  
In contrast to microglia, TLR4 expression by astrocytes remains an open 
question. Farina and collegues (2005) have demonstrated TLR4 cell surface 
expression in vitro while other groups (Laflamme and Rivest, 2001; 
Lehnardt et al., 2002; 2003) described the presence of TLR4 in vivo. 
Receptor functional analyses normally focus on the product of activation 
which, in our case, are cytokines. As L-LME-treated and nominally 
microglia-free astrocytes were unresponsive in terms of IL-1β, IL-6 and 
TNF-α gene expression upon TLR-ligand engagement, we wished to exclude 
the possibility of an alteration/absence for the cognate cell surface 
receptor complex. 
Western blot analysis using specific antibodies against TLR4, CD14 and 
MD2 shows the presence of all members of the protein complex after L-
LME treatment. No differences in protein expression were evident 
between enriched and L-LME-purified astrocytes (Fig. 4.14A).  
Confocal microscopy shows co-expression of GFAP and TLR4 in both 
astrocyte-enriched cultures and in purified astrocytes (Fig. 4.14B). 
Moreover, we used a fluorescent conjugate of LPS from E. coli (Life 
Technologies, L-23351) to follow LPS binding and transport processes after 
30 minutes of treatment.  Cells were treated with LPS conjugated with 
Alexa Fluor 488 and GFAP, as astrocytic marker, to monitor real-time 
changes in cellular response to LPS (Fig. 4.14C). 
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Overall our experiments show the presence of the LPS receptor complex on 
the cell surface of cortical astrocytes and its ability to bind and internalize 
LPS after 30 minutes of exposure.  
 
Fig. 4.14 Analysis of LPS receptor complex components using enriched and 
purified (L-LME-treated) rat cortical astrocytes. (A) Western blot 
analysis of TLR4, CD14 and MD2 expression. (B) Confocal microscopy 
shows co-expression of GFAP and TLR4 both in astrocyte-enriched and 
purified astrocytes. (C) LPS conjugated with Alexa Fluor 488 co-localizes 
with GFAP, after 30 minutes of treatment. 
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4.5. LPS, zymosan and poly(I:C) modulate TLR expression in purified 
astrocytes 
4.5.1. TLR modulation in astrocytes challenged with LPS 
Immune responses in the CNS are mainly attributed to microglia (Rivest, 
2009), due to the capacity of these cells to present antigens (Gorina et al., 
2011). However, astrocytes are the most abundant CNS cell type. Since we 
have demonstrated the presence of TLRs in purified astrocyte cell 
cultures, we asked whether TLR ligands are able to modulate features of 
immune responses regulating TLR protein expression, indepdendent of 
cytokine production. 
TLR gene expression was studied by Real-Time PCR using enriched 
astrocyte cell cultures without or with a prior exposure to L-LME to 
deplete the residual microglial cell population. Cells were challenged with 
100 ng/mL LPS for 6 or 24 hours. TLR4 mRNA levels were significantly 
down-regulated both in enriched astrocytes (0.71 ± 0.03 vs CTR ± 0.03) and 
purified astrocytes (0.11 ± 0.01 vs CTR ± 0.03) at 6 hours (Fig. 4.15A, top 
left panel) and 24 hours (Fig. 4.8A, top right panel). In contrast to TLR4, 
LPS significantly up-regulated TLR2 mRNA levels after 6 hours in enriched 
as well as in purified astrocytes (Fig. 4.15A, middle left panel); this effect 
was still evident after 24 hours (Fig. 4.15A, middle right panel). LPS 
treatment significantly raised TLR3 mRNA at after 6 hours in enriched 
astrocytes only; there was a non-significant trend to increase in all other 
samples (Fig. 4.15A, bottom left and right panels). Interestingly, L-LME 
treatment reduced, but did not abolish basal TLR4 mRNA (0.22 ± 0.05 vs 
CTR ± 0.03 for TLR4; 0.44 ± 0.12 vs CTR ± 0.06 for TLR3; 0.13 ± 0.01 vs 
CTR ± 0.14 for TLR2). 
Analyses of TLR cell surface expression of were performed using FACS 
utilizing purified astrocyte cultures challenged with LPS for 1, 6, and 24 
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hours. While the percentage of TLR4-positive cells increased already at 1 
hour, the amounts of cell surface-expressed receptor did not change (Fig. 
4.15B, bar chart). TLR3, but not TLR2 is modulated due to the treatment 
(Fig. 4.15B). These data demonstrate that the percentage of positive cells 
does not always follow the direction of the MFI, indicating a cellular 
regulation of the receptor exposure.   
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Fig. 4.15A. Effect of LPS (100 ng/ml) treatment on TLR gene expression in enriched and 
purified rat cortical astrocyte cell cultures. TLR mRNAs were quantified by Real-Time 
PCR after 6 hours and 24 hours of treatment. Data are means ± SEM (triplicate culture 
wells) normalized to GAPDH levels, and are representative of 3 experiments. Statistical 
significance, calculated by Dunnett’s multiple comparision test vs untreated cells: 
p≤0.05*; p≤0.01**; p≤0.001*** 
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Fig. 4.15B. Effect of LPS treatment on astrocyte expression of TLR proteins by FCM 
analysis. Enriched or purified rat cortical astrocytes were challenged with 100 ng/ml 
LPS for 1, 6 and 24 hours. Data reported in tracings are expressed as percentage of 
positive cells (blue profiles) with respect to controls (grey profiles) prepared using 
secondary antibodies. Bar charts show the relative MFI values. Data are means ± SEM 
(duplicate culture wells) normalized to secondary antibody MFI. Statistical significance, 
calculated by Dunnett’s multiple comparision test vs untreated cells: p≤0.05*; p≤0.01**; 
p≤0.001*** 
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4.5.2. TLRs modulation in astrocytes challenged with zymosan 
Astrocytes were stimulated with zymosan (10 µg/mL) for 6 and 24 hours. 
Not unexpectedly, this TLR2 ligand modulates its target receptor, inducing 
a marked and significant up-regulation in purified astrocytes after 6 hours 
(10.85 ± 1.15 vs CTR ± 0.2) (Fig. 4.16A, middle left panel) and also after 24 
hours (3.06 ± 0.16 vs CTR ± 0.2) (Fig. 4.16A, middle right panel). TLR2 
agonist activity regulates also TLR4 and TLR3 mRNA. Transcript levels for 
TLR4 mRNA are down-regulated after 6 hours (0.0.12 ± 0.02 vs CTR ± 
0.06) (Fig. 4.16A, top left panel) and 24 hours (0.37 ± 0.02 vs CTR ± 0.15) 
(Fig. 4.16A, top right panel). TLR3 mRNA does not statistically change in 6 
hours (1.14 ± 0.08 vs CTR ± 0.07) (Fig. 4.9A, bottom left panel) but is 
significantly raised after 24 hours (1.55 ± 0.0 vs CTR ± 0.02) (Fig. 4.16A, 
bottom right panel). 
FCM analyses for protein expression show that the percentage of positive 
cells marked for TLR2 is strongly reduced by treatment, as confirmed also 
by MFI (Fig. 4.9B). TLR3 is not influenced by the treatment considering 
both the percentage of positive cells and MFI. TLR4 expression on the cell 
surface, as TLR2 decreases already after 1 hour and remains low until 24 
hours (Fig. 4.9B). 
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Fig. 4.16A. Effect of zymosan on TLR gene expression in enriched and purified rat 
cortical astrocyte cell cultures. TLR mRNAs were quantified by Real-Time PCR after 6 
hours and 24 hours of treatment. Data are means ± SEM (triplicate culture wells) 
normalized to GAPDH levels, and are representative of 3 experiments. Statistical 
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significance, calculated by Dunnett’s multiple comparision test vs untreated cells: 
p≤0.05*; p≤0.01**; p≤0.001*** 
 
 
 
Fig. 4.16B. Effect of zymosan on astrocyte expression of TLR proteins by FCM 
analysis. Enriched or purified rat cortical astrocytes were challenged with 10 µg/mL 
zymosan for 1, 6 and 24 hours. Data reported in tracings are expressed as percentage 
of positive cells (blue profiles) with respect to controls (grey profiles) prepared using 
secondary antibodies. Bar charts show the relative MFI values. Data are means ± SEM 
(duplicate culture wells) normalized to secondary antibody MFI. Statistical 
significance, calculated by Dunnett’s multiple comparision test vs untreated cells: 
p≤0.05*; p≤0.01**; p≤0.001*** 
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4.5.3. TLR modulation in astrocytes challenged with poly(I:C) 
Astrocytes were stimulated with poly(I:C) (50 µg/mL) for 6 and 24 hours 
and TLR gene expression analysed. Poly(I:C) treatment of purified 
astrocytes produced a significant, robust increase in TLR3 mRNA after 6 
hours (3.56 ± 0.16 vs CTR ± 0.07) and 24 hours (2.18 ± 0.10 vs CTR ± 0.12) 
(Fig. 4.17A, bottom left and right panels, respectively). Futher, poly(I:C) 
induced a strong and significant rise in TLR2 gene expression after 6 hours 
(11.24 ± 0.22 vs CTR ± 0.01) and after 24 hours (2.26 ± 0.15 vs CTR ± 0.15) 
(Fig. 4.17A, middle left and right panels, respectively). In contrast, 
transcript levels for TLR4 were statistically lower versus control after 6 
hours (0.29 ± 0.05 vs CTR ± 0.11) (Fig. 4.17A, top left panel); the effect was 
not evident at the 24-hour time point (0.47 ± 0.03 vs CTR ± 0.19) (Fig. 
4.17A, top right panel).  
The effects of poly(I:C) on TLR protein expression were studied using 
FCM. The percentage of TLR3-positive cells after 6 hours was found to be 
decreased; this was confirmed by MFI. TLR3 expression on the endosomal 
membrane was not modulated by poly(I:C) treatment; these data are in 
agreement with MFI analysis (Fig. 4.17B). TLR2 and TLR4 were up-
regulated after 6 hours of poly(I:C) treatment (Fig 4.17B). 
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Fig. 4.17A. Effect of poly(I:C) on TLR gene expression in enriched and purified rat 
cortical astrocyte cell cultures. TLR mRNAs were quantified by Real-Time PCR after 6 
hours and 24 hours of treatment. Data are means ± SEM (triplicate culture wells) 
normalized to GAPDH levels, and are representative of 3 experiments. Statistical 
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significance, calculated by Dunnett’s multiple comparision test vs untreated cells: 
p≤0.05*; p≤0.01**; p≤0.001*** 
 
 
 
Fig. 4.17B. Effect of poly(I:C) on astrocyte expression of TLR proteins by FCM analysis. 
Enriched or purified rat cortical astrocytes were challenged with 50 µg/mL poly(I:C) for 
1, 6 and 24 hours. Data reported in tracings are expressed as percentage of positive 
cells (blue profiles) with respect to controls (grey profiles) prepared using secondary 
antibodies. Bar charts show the relative MFI values. Data are means ± SEM (duplicate 
culture wells) normalized to secondary antibody MFI. Statistical significance, calculated 
by Dunnett’s multiple comparision test vs untreated cells: p≤0.05*; p≤0.01**; p≤0.001*** 
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4.6. Reintroduction of microglia restores purified astrocytes 
responsiveness to TLR agonists 
The above results suggest that microglia-astrocyte interaction may be a 
necessary condition to elicit responsiveness to LPS, at least in terms of 
inflammatory mediator production. To test this possibility,we reconstituted 
a pro-inflammatory culture profile in cultures of L-LME-purified astrocytes 
by adding increasing numbers of purified microglia (9,000, 18,000, 36,000 
cells) (Fig. 4.18). Interestingly, the reintroduction of microglia restored 
LPS, zymosan and poly(I:C) responsiveness (last three bars in each panel)  
in term of cytokine gene expression after 6 hours treatment (Fig. 4.18) and 
protein release (Fig. 4.19) after 6 hours treatment.  
 
 
Fig. 4.18. Microglial cell addition to purified astrocytes restores a pro-inflammatory 
profile when presented with a subsequent challenge with TLR agonists for 6 hours. 
Cytokine gene expression analysis was carried out by Real Time PCR. Data are means ± 
SEM (triplicate culture wells) normalized to GAPDH levels, and are representative of 3 
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experiments. Statistical significance, calculated by Dunnett’s multiple comparision test vs 
untreated cells: p≤0.05*; p≤0.01**; p≤0.001*** 
 
 
Fig. 4.19. Recovery  of a pro-inflammatory 
profile for purified astrocytes following 
addition of increasing numbers of 
microglial cells (CM) and challenge with 
TLR agonist. Cytokine release was  
measured by ELISA. Statistical 
significance, calculated by Dunnett’s 
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multiple comparision test vs untreated 
cells: p≤0.05*; p≤0.01**; p≤0.001*** 
 
 
The effect of microglial cell addition was examined in greater detail, 
choosing IL-6 release as an example. As Fig. 4.20 shows, equivalent 
numbers of microglia alone, when stimulated with LPS (100 ng/ml) for 24 
hours released far less IL-6 than when cultured in the presence of L-LME 
treated (purified). However, cultures containing enriched astrocytes 
(approximate microglia content: 2,500 cells) generated an amount of IL-6 
similar to that for L-LME-treated astrocytes with 20,000 microglia. This 
result suggests that the astrocyte/microglia 'co-culture' is more 
responsive when the two cell types develop together. 
 
Fig. 4.20. Addition of microglia to L-LME-treated astrocytes restores LPS-induced IL-6 
release. The same numbers of microglia were cultured in a parallel plate, treated with LPS 
as above and analysed for cytokine content after 24 hours. All data are means ± SEM 
(n=3). 
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4.7 Microglia-astrocyte communication: evaluation of possible 
mechanism 
Earlier studies pointed to a lack of soluble astrocyte-derived factors as 
being responsible for imparting LPS sensitivity to microglia in terms of 
mediator release (Barbierato et al., 2013), suggesting instead a role for 
physical contact between these two cell populations. This question was 
examined further using a two-chamber cell culture system, in which an 
upper layer (insert) of microglia is separated from a lower layer of 
astrocytes by means of a porous membrane that allows for communication 
between the compartments. A 24-hour LPS incubation of astrocytes only 
resulted in a very small quantity of IL-1β release (Table 1) but much 
greater intracellular accumulation, which was reduced by >90% following L-
LME treatment (Table 2). LPS addition to the microglia compartment also 
produced a small release of IL-1β but far more intracellularly; 
interestingly, the presence of LPS in the lower chamber also resulted in IL-
1β release by microglia (most likely a result of trans-chamber LPS passage). 
LPS-treated microglia did not influence IL-1β expression by L-LME-treated 
astrocytes, either extra- or intracellularly. Although the intracellular 
content of IL-1β in microglia was greater in the presence of LPS- (and L-
LME)-treated astrocytes compared to direct LPS treatment of the 
microglia (2218 ± 143 and 1407 ± 63 pg, respectively) values for IL-1β 
release in both cases were similar.  
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TABLE 1: IL-1β Release (pg/chamber)  
Astrocytes Microglia 
Insert LPS No L-LME + L-LME Control LPS 
– – 0  0 0  0 --- --- 
– + 63  5 0  6 --- --- 
+ – --- 0  0 0  0 --- 
+ – --- 0  0 --- 30  2 
+ + --- 0  0 34  4 --- 
 
TABLE 2: Intracellular IL-1β (pg/chamber) 
Astrocytes Microglia 
Insert LPS No L-LME + L-LME Control LPS 
– – 148  30 169  53 --- --- 
– + 1447  42 140  8 --- --- 
+ – --- 133  9 0  0 --- 
+ – --- 158  13 --- 1407  63 
+ + --- 146  24 2218  143 --- 
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5.DISCUSSION 
Toll-like receptors (TLRs) are best known for recognizing pathogens and 
initiating an innate immune response to protect the host. However, they 
also detect tissue damage and induce sterile inflammation upon the binding 
of endogenous ligands released by stressed or injured cells (Heiman et al., 
2014) (Tables 2 and 3). 
 
In the CNS, microglia are the best-characterized cell type expressing 
TLRs. They constantly survey their environment and can rapidly switch to 
an “activated” phenotype, producing factors that influence surrounding 
astrocytes. Upon coming into contact with a danger signal microglia undergo 
activation, a process which induces engagement of other immune system 
cells and repair. Left unchecked, protracted inflammatory stimuli lead to a 
strong release of pro-inflammatory factors and consequent neuron cell 
death (Glass et al., 2010). Astrocytes, the predominant CNS cell type, also 
become reactive following injury and have been implicated in the 
pathogenesis of CNS inflammation (Sofroniew and Vinters, 2010; John et 
al., 2005; Medeiros and Laferla, 2013) and neuropathic pain (Chen et al., 
2012). As succinctly stated by Nathan and Ding (2010), "The problem with 
inflammation is not how often it starts, but how often it fails to subside". 
 
The interplay between astrocytes and microglia and their associated pro-
inflammatory environment is, no doubt, a key element in the pathogenesis 
of chronic pain and neuropathic pain, neurodegenerative diseases, stroke, 
spinal cord injury, and perhaps even neuropsychiatric disorders (Carson et 
al., 2006; Melchior et al., 2006; Herbert et al., 2005). 
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In the present study we used a series of TLR subtype-selective agonists 
(LPS for TLR4, zymosan for TLR2 and poly(I:C) for TLR3) to generate a 
glial cell-based experimental in vitro model of neuroinflammation, which can 
be applied to investigate the induction and release of pro-inflammatory 
mediators upon TLR activation.  
 
Cortical purified microglia subjected to pathogenic stimuli responded 
already by 6 hours with the production of mRNAs coding for pro-
inflammatory genes. After a longer stimulation period, all mRNAs were 
translated into the respective cytokine polypeptide which was released into 
the culture medium. Furthermore, these TLR ligands were capable of 
modulating the expression of both cell surface (TLR2/TLR4) and endosomal 
membrane (TLR3) TLRs. This modulation following TLR ligand presentation 
could be the consequence of several factors. Indeed, it was possible to 
observe both pre-existent protein level modulation (internalization/ligand-
binding/receptor degradation/receptor exposition) and genetic regulation 
(up- or down-regulation of mRNAs coding for TLRs). 
Intriguingly, not only did a given TLR ligand modulate its own receptor’s 
expression, but also that of other TLRs as well. This last result proposes 
the existence of a cross-talk mechanism in the TLR pathway(s) which may 
have important consequences for how multiple TLR isoforms respond to 
stress/injury, for example as in neuropathic pain. Enriched astrocytes from 
rat cortex were responsive to all TLR agonists, as well, with induction of 
the genes for IL-1β, IL-6 and TNF-α.  
 
The above findings obtained with ex vivo glial cell systems illustrate a 
widely-utilized approach to investigate activation of these cell types during 
inflammatory processes, and are often preferred over in vivo analysis 
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because of the latter’s complexity. While microglia can be easily obtained 
as a highly purified (>99%) cell population (as demonstrated in this project), 
achieving highly purified astrocyte cultures is more difficult owing to 
minor, and variable, percentages of residual contaminating microglia (Saura, 
2007). 
 
In order to study astrocyte behaviours without potential interference 
from contaminating microglia, L-LME was used to deplete the enriched 
astrocyte monolayers of residual microglia. Microglia depletion was 
confirmed by the disappearance of Iba-1 gene and protein expression from 
these cultures. 
 
L-LME treatment abolished TLR agonist induction and release of pro-
inflammatory cytokines from cortical astrocytes. We asked if this 
unresponsiveness by nominally microglia-free astrocytes in terms of IL-1β, 
IL-6 and TNF-α gene expression, upon TLR-ligand engagement, could be due 
to possible alteration/absence of the cognate cell surface receptor 
complex. In contrast to microglia, TLR4 expression by astrocytes remains 
an open question. Farina and colleagues (2005) have demonstrated TLR4 
cell surface expression in vitro while other groups (Laflamme and Rivest, 
2001; Lehnardt et al., 2002; 2003) described the presence of TLR4 in vivo. 
In the present study, astrocytes striped of microglia and incubated with a 
fluorescent LPS showed co-localization of immunoreactivity for GFAP and 
the TLR4-specific ligand. In addition, it was possible to demonstrate the 
presence of the TLR4 co-receptors MD2 and CD14. Moreover, purified 
astrocytes challenged with TLR agonists responded with a modulation of 
both its cognate receptor as well as other TLRs. These results are 
important in that they place astrocytes in the context of the inflammatory 
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process by being able to detect and respond to pro-inflammatory signals 
even though they do not produce pro-inflammatory mediators – at least 
those evaluated in this study. 
 
It is worth stressing the point that numerous studies have described the 
use of astrocyte-enriched cultures to study their capability to elaborate 
inflammation-related molecules, e.g. cytokines, chemokines, and adhesion 
molecules (Saura, 2007). In the present study, we clearly demonstrate that 
oftentimes these reports wrongly assume that astrocytes are the cell type 
responsible for the observed effect. Rather, the effects may well be due 
to a minor population of contaminating microglia. To further emphasize this 
view, we performed experiments whereby fixed numbers of purified 
microglia (10% of contaminating cells final) were introduced to cultures of 
(L-LME) purified astrocytes. Doing so restored TLR responsiveness of the 
latter in terms of IL-1β, IL-6 and TNF-α gene expression. 
 
The TLR agonist responsiveness of these microglia-astrocyte co-cultures 
was evident also at the level of mediator release. When an equivalent 
number of microglia alone was challenged with a given TLR agonist cytokine 
output (in terms of absolute amount) into the culture medium was 
surprisingly less than the amount released when the same number of 
microglia had been added to the astrocytes. These data show that 
astrocytes alone are unable to respond when challenged with exogenous 
TLR2/3/4 ligands. The fact that the response was more robust when 
microglia were in the presence of astrocytes suggests the existence of a 
synergism between astrocytes and microglia. It bears noting that although 
the 'co-cultures' express pro-inflammatory cytokines after TLR agonist 
stimulation, the absolute levels are inferior to those measured in enriched 
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astrocytes (<5% of contaminating microglia) – that latter having far fewer 
microglia than the numbers added to reconstitute the co-culture. 
Conceivably, microglia which are ‘nurtured’ by astrocytes may be more 
responsive to an inflammatory stimulus than cultures in which the microglia 
are chemically ‘stripped’ and then re-introduced. This tenet, if upheld in 
vivo has important implications for how these two glial cell types may 
interact in pathology. 
 
To further address the issue of whether microglial cell activation in the 
presence of astrocytes results from either physical interaction between 
cell membranes or chemical induction mediated by the release of 
mediator(s) into the culture medium, a “Transwell insert” system was used.  
In our study we pointed to a lack of soluble astrocyte-derived factors as 
being responsible for imparting LPS sensitivity to microglia in terms of 
mediator release, suggesting instead a role for physical contact between 
these two cell populations. The presence of LPS in the lower chamber 
resulted in IL-1β release by microglia (plated in the upper chamber, 
indicating trans-chamber LPS passage) but this release did not influence 
IL-1β expression by purified astrocytes, either extra- or intracellularly. 
The molecular basis for the observed astrocyte-microglia interaction 
remains to be clarified.  
 
In conclusion, the astrocyte/microglia co-culture paradigm described here 
may represent a useful starting point to elucidate the cross-talk 
mechanisms underlying astrocyte- and microglia-specific responses after 
TLR activation during, although not limited to, CNS inflammation. 
To more fully understand how glial cells respond to inflammatory stimuli, 
future studies could explore intracellular signal transduction pathways. 
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Microglia themselves respond to TLR agonists, undergoing activation to 
release cytokines. Since purified astrocytes express TLRs - at least those 
evaluated in this study - but do not elaborate either transcription or 
translation for IL-1β, IL-6 and TNF-α, it is possible to speculate a 
different regulation of NF-kB, IRF3 or IRF7 signalling. It is even 
conceivable that transcription factor activation is under unknown control 
mechanisms or, alternatively, astrocytes might need a further signal(s) to 
induce activation. In spite of the large amount of data published to date, 
this field of research has much to reveal still. 
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